



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA



42nd Annual Congress of the

*Canadian
Neurological
Sciences
Federation*

*42ème congrès annuel de la
Fédération des
sciences neurologiques
du Canada*



Final Program / Programme final

New age. Healthy age.

As a leading research-based pharmaceutical company, we're committed to making every age a healthy age. Because we believe in great beginnings, too.



Working for a healthier world™


www.pfizer.ca

© 2006, Pfizer Canada Inc.
Kirkland, Quebec H9J 2M5



Canada's Research-Based
Pharmaceutical Companies

™ Pfizer Inc., used under license.



WELCOME MESSAGE

Scientific Program Chair, John Stewart, Vice Chair Mike Tymianski, their Committee members, the CNSF Board, staff and I welcome you to the 42nd Congress of the Canadian Neurological Sciences Federation.

We hope you will enjoy the Program this year. It won't take you long to discover some of the exciting changes we've made to the Congress in our continuing effort to provide our delegates the most comprehensive meeting of neurologists, neurosurgeons and neuroscientists in the country.

Some features new to the Congress this year that you should take note of are:

1. A Distinguished Guest Lecture. We are pleased to announce that Michael Bliss will be speaking on "From Osler to Cushing-The Rise of Medicine, The Rise of Neurosurgery" in the first of what we are sure will be a highly anticipated Congress feature in the years to come.
2. Digital Posters on display in the exhibit area. Fully navigable and categorized according to station, we are sure this departure from physical posters will give greater value to interested delegates and authors.
3. A smaller more intimate exhibit area featuring most of this year's sponsors, whose support makes this Congress possible. Please visit the exhibit area! It is important to do so.

During this Congress there will be opportunities for you to:

1. Network with colleagues, mentors and friends.
2. Rejuvenate your practice with additional knowledge and skill.
3. Stimulate your thinking.
4. Earn Section 1 MOC Credits.
5. Work on your personal learning needs.

We hope you find this Congress as educational, broad based, innovative, creative and exciting as we do.

Please make sure you tell us how we are doing by completing the Session Specific Evaluation Forms, which will be in the Course and other session rooms, and the Overall Congress Evaluation available on line and in your registration portfolio. It is important that you provide us this feedback so we can continue to improve and better meet your learning needs.

Again, welcome and Thank you.

Yours truly,



Mark Hamilton
President
CNSF



John Stewart
Chair
Scientific Program Committee

CNSF Executive Committee

Mark Hamilton, *CNSF Chair*
Garth Bray, *CNSF Vice-President*
Brian Wheelock, *CNSF Vice-President*
Dan Morin, *CNSF Chief Executive Officer*
(*ex-officio*)

Scientific Program Committee

John Stewart, *Chair CNS*
Mike Tymianski, *Vice-Chair*
Jeanne Teitelbaum, *CNS*
Michael Hill, *CNS*
Christopher Honey, *CNSS*
Eric Massicotte, *CNSS*
Joseph Chu, *CSCN*

Seyed Mirsattari, *CSCN*
Juliette Hukin, *CACN*
Elaine Wirrell, *CACN*
Susan Brien, *Chair, Professional Development Committee*
Brian Wheelock, *CNSF Vice-President*
Carmela Tartaglia, *Resident Neurology*
Artur Szymczak, *Resident Neurosurgery*

Congress Organizers

Advance Group, Conference Management
Suite 101-1444 Alberni Street
Vancouver, BC V6G 2Z4
Tel: 1-800-555-1099 (ext 2) Fax: (604) 685-3521
E-mail: cnsf2007@advance-group.com
Contact: Jo-ann Roy, Conference Manager

Canadian Neurological Sciences Federation


709 – 7015 Macleod Trail SW
Calgary, AB,
Canada T2H 2K6
Tel: (403) 229-9544
Fax: (403) 229-1661
E-mail: brett-windle@cnsfederation.org



**A leader in
hemostasis
research and
proud sponsor
of the Canadian
Neurological
Sciences
Federation
42nd Annual
Congress**



Partners in the Management of Acute Stroke Care



We Innovate Healthcare



TABLE OF CONTENTS / TABLE DES MATIÈRES

Daily Events Calendar	4
Scientific Sessions	
Business Meetings	
Social Events	
Daily Scientific Sessions	6
Meetings at a Glance	
Exhibition Hall	7
General Meeting Information	8
Maintenance of Certification	10
How to obtain CME credits	
Plenary Guest Speakers	11
Detailed Scientific Program	
Tuesday, June 19, 2007	17
Wednesday, June 20, 2007	21
Thursday, June 21, 2007	25
Friday, June 22, 2007	26
Winners of the 2007 Society Prizes	32
Platform Presentations	33
Poster Presentations	40
2007 Exhibitors	46
Accreditation FRCPC ou FRCSC	10
Comment obtenir des crédits CME	
Reseignements D'ordre Général	50
Programme scientifique	
Réunion d'affaires	
Activités sociales	
Programme des Activités	52
Programme Scientifique	
Mardi 19 juin 2007	54
Mercredi 20 juin 2007	58
Jeudi 21 juin 2007	62
Vendredi 22 juin 2007	63

Monday, June 18, 2007

09:00-16:30	CNSF/CJNS Board & Planning Meetings	Drawing Room Fairmont
09:00-09:30	CJNS Audit Committee	Boardroom Fairmont
09:30-10:00	CNSF Audit Committee	Boardroom Fairmont
16:30-17:30	CACN Council Meeting	Drawing Room Fairmont
15:00-17:00	Speaker Preparation Room	Salon 7

Tuesday, June 19, 2007

07:30-18:30	Registration	Meeting Level Foyer
07:00-18:00	Speaker Preparation Room	Salon 7
07:30-08:30	CNS Alberta Chapter AGM	Salon 1
08:00-17:00	Neurobiology Review Course	Salon 4
08:30-17:00	ALS Strategies for Quality Life/Quality Care Symposium Course	Salon 3
08:30-17:00	Child Neurology Day	Salon 2
09:00-11:00	CNSF Professional Development Committee	Salon 5/6
10:00-12:00	CNSF Scientific Program Committee	Salon 5/6
12:00-13:30	ALS Lunch	Salon 12
12:00-13:00	Neurology Residents CNS Meeting	Wedgewood Fairmont
12:00-13:00	CSCN EMG Committee	Drawing Room Fairmont
13:00-14:00	CSCN EEG Committee	Drawing Room Fairmont
12:30-16:30	CNS Education & Manpower, RC Specialty Committee Neurology	Salon 1
13:00-14:00	CJNS Editorial Board	Salon 19/20
14:00-15:00	CJNS Publications Committee	Salon 19/20
13:00-15:30	ALS Breakout 2	Salon 15/16
13:00-15:30	ALS Breakout 3	Salon 13/14
16:30-18:00	CSCN Council Meeting	Salon 1
16:30-18:00	CNSS Council Meeting	Salon 20
16:30-18:00	CNS Council Meeting	Salon 19
16:30-17:30	Neurosurgery Residents Business Meeting	Salon 17
17:00-18:00	CACN Annual General Meeting	Salon 15/16
18:00-20:00	Epilepsy Video Session (Course)	Salon 4
18:00-20:00	Movement Disorders	Wedgewood Fairmont
18:00-20:00	ALS SIG	Jasper Room Fairmont
18:00-20:00	Neuromuscular SIG	Salon 3
18:00-20:00	Neurosurgery Residents Education Meeting SIG	Drawing Room Fairmont
18:00-20:00	Undergraduate Neurological Education	Salon 13 & 14
18:30	CACN Dinner - Ruth's Chris Steak House	

Wednesday, June 20, 2007

07:00-18:30	Registration	Meeting Level Foyer
07:00-18:00	Speaker Preparation Room	Salon 7
07:00-08:00	Pediatric Neurosurgery	Salon 1
08:00-16:00	Exhibit Move-in (For Exhibitors)	Salons 8,9,10 & 11
08:30-10:30	Grand Opening Plenary - Scientific & Technical Advances in the Clinical Neurosciences	Salon 12
10:45-12:15	Chair's Select Plenary Presentation	Salon 12
12:00-13:00	Canadian Movement Disorders AGM	Salon 1
12:00-13:00	Canadian Neuromuscular Group	Salon 17/18
13:00-14:00	CBANHC (Canadian Brain & Nerve Health Coalition) Meeting	Salon 5
14:00-17:30	Spine Course	Wedgewood Fairmont
14:00-15:30	EMG Workshop 1	Salon 15
14:00-15:30	EMG Workshop 2	Salon 16
14:00-17:30	EMG Workshop 3	University of Alberta
14:00-15:30	EMG Workshop 4	Salon 19
14:00-17:30	Neurocritical Care Course	Salon 3
14:00-17:30	Epilepsy Course	Jasper Room Fairmont
14:00-17:30	Neuropathic Pain Course	Drawing Room Fairmont
16:00-17:30	EMG Workshop 1	Salon 15
16:00-17:30	EMG Workshop 2	Salon 16
16:00-17:30	EMG Workshop 4	Salon 19
14:00-17:30	Stroke Course	Salon 2
17:30-19:00	Opening of Exhibits (Exhibitors' Reception)	Salons 8,9,10 & 11
19:00-21:00	Presidents' Reception	Empire Ballroom/Foyer/Terrace Fairmont

Thursday, June 21, 2007

06:15	CANN Fun Run/Walk for Neuroscience Nursing Research	Go to www.cann.ca for further information
07:00-18:30	Registration	Meeting Level Foyer
07:00-18:00	Speaker Preparation Room	Salon 7
07:30-08:30	Canadian League Against Epilepsy Meeting	Salon 18
07:30-08:30	Canadian Neurocritical Care Group	Salon 17
07:30-08:30	CNSF Affiliate Societies Meeting	Salon 1
07:00-08:30	Canadian Board of Registration of EEG Technologists (CBRET)	Salon 19
08:30-10:00	Plenary - CNS, CACN & CSCN Neurology	Salon 12
08:30-10:00	Plenary - CNSS Neurosurgery	Salon 2
10:15-12:30	Platform Session (General Neurosurgery 1)	Salon 4
10:15-12:30	Platform Session (MS)	Salon 2
10:15-12:30	Platform Session (Stroke Neurology)	Salon 3
10:15-12:30	Platform Session (General Neurology)	Salon 12
10:15-12:30	Platform Session (General Pediatric Neurology)	Salon 5 & 6
10:15-12:30	Platform Session (Epilepsy & EEG)	Salon 13/14
12:30-14:00	Lunch in Exhibit Hall & Poster Viewing	Salons 8,9,10 & 11
14:00-16:30	Platform Session (General Neurosurgery 2)	Salon 4
14:00-16:30	Platform Session (Spine)	Salon 2
14:00-16:30	Platform Session (Neuro-Oncology)	Salon 3
14:00-16:30	Platform Session (Cerebrovascular Surgery)	Salon 12
14:00-16:30	Platform Session (Neuromuscular)	Salon 5 & 6
14:00-16:30	Platform Session (Pediatric Epilepsy)	Salon 13/14
14:00-16:30	Platform Session (Critical Care)	Salon 15/16
16:30-18:00	Canadian Pediatric Neuromuscular Group	Salon 1
16:30-18:00	Digital Poster & Exhibit Viewing	Salons 8,9,10 & 11
17:00-18:00	CNS Foundation Meeting	Salon 19
18:00-19:00	Residents' Soiree	Salon 5/6
19:00	President's Dinner	Hall D

Friday, June 22, 2007

07:00-13:30	Registration	Meeting Level Foyer
07:30-14:30	Speaker Preparation Room	Salon 7
07:30-08:30	Canadian Headache Society AGM	Salon 20
07:00-08:30	CSCN AGM	Salon 6
07:00-08:30	Canadian Neurosurgical Society (CNSS) AGM	Salon 13/14
07:00-08:30	Canadian Neurological Society (CNS) AGM	Salon 15/16
08:30-09:30	Distinguished guest lecture	Salon 12
09:30-09:50	CBANHC Report	Salon 12
09:50-10:00	Reviewer of the Year Award Presentation & Introduction of new CJNS Editor	Salon 12
09:30-15:00	Poster & Exhibit Viewing	Salons 8,9,10 & 11
10:15-12:00	Grand Rounds	Salon 12
10:30-12:00	CBANHC Meeting	Salon 17 & 18
12:00-13:30	Lunch in Exhibit Hall & Poster Tours	Salons 8,9,10 & 11
12:00-13:30	Royal College Committee Neurosurgery	Salon 17 & 18
13:30-17:00	Headache Course	Salon 2
13:30-17:00	What's New In Neurosurgery Course	Drawing Room Fairmont
13:30-17:00	EEG Course	Salon 4
13:30-17:00	Dementia Course	Salon 3
13:30-17:00	MS Course	Salons 5/6
13:30-17:00	What's New in Neurology Course	Wedgewood Fairmont
13:30-17:00	Neuromuscular Course	Salon 12
17:00-18:00	CNSF/CJNS Board Meeting	Salon 17 & 18
17:00-22:00	Canadian Headache Outpatient & Data Base Group Meeting	Salon 19

Saturday, June 23, 2007

08:00-09:30	ThinkFirst Canada Annual General Meeting - Winterlake Room, Sutton Place Hotel
09:30-12:30	ThinkFirst Canada Chapters Meeting - Winterlake Room, Sutton Place Hotel

Abbreviation Guide

Annual General Meeting (AGM)
 Canadian Association of Child Neurology (CACN)
 Canadian Neurological Sciences Federation (CNSF)
 Canadian Journal of Neurological Sciences (CJNS)
 Canadian Neurological Society (CNS)
 Canadian Neurosurgical Society (CNSS)
 Canadian Society of Clinical Neurophysiologists (CSCN)
 Special Interest Groups (SIGs)

Blue type shows scientific program events;
 Black shows business and other meetings.

SCIENTIFIC SESSIONS – MEETING AT A GLANCE

TUESDAY June 19, 2007

08:00-17:00
Neurobiology Review Course
page 17

08:30-17:00
ALS Strategies for Quality
Life/Quality Care
page 18

08:30-17:00
Child Neurology Day -
Controversies and Advances in
Neonatal Neurology
page 19

18:00-20:00
Epilepsy Video Session
page 20

18:00-20:00
Movement Disorders
Management - Drugs to Surgery
page 20

18:00-20:00
SPECIAL INTEREST GROUPS
ALS, Neuromuscular,
Neurosurgery Residents'
Education, Undergraduate
Neurological Education
page 20

WEDNESDAY June 20, 2007

08:30-10:30
Grand Opening Plenary:
Scientific and Technical
Advances in the Clinical
Neurosciences
page 21

10:45-12:15
Chair's Select Plenary
Presentation
page 21

14:00-17:30
Neuropathic Pain:
Pathophysiology, Prevention
and Management
page 21

14:00-17:30
Spine Course - The Triage and
Management of the Cervical
Spondylotic Myelopathy Patient
page 22

14:00-17:30
Clinical Electromyography
Course
page 23

14:00-17:30
Stroke Course
page 23

14:00-17:30
Epilepsy Course: Intractable
Epilepsy
page 24

14:00-17:30
Neurocritical Care Course
page 24

THURSDAY June 21, 2007

08:30-10:00
Plenary Session: CNS, CACN and
CSCN Neurology
page 25

08:30-10:00
Plenary Session: CNSS
Neurosurgery
page 25

10:15-12:30
Platform Sessions
(6 concurrent)
page 25

12:30-14:00
Digital Poster and Exhibit
Viewing
page 25

14:00-16:30
Platform Sessions
(7 concurrent)
page 25

16:30-18:00
Digital Poster and Exhibit
Viewing
page 25

FRIDAY June 22, 2007

08:30-09:30
Distinguished Guest Lecturer
page 26

09:30-09:50
The CBANHC Report
page 26

09:50-10:15
Digital Poster and Exhibit
Viewing
page 26

10:15-12:00
Grand Rounds
page 26

12:00-13:30
Digital Poster and Exhibit
Viewing
page 26

13:30-17:00
Headache Course
page 27

13:30-17:00
What's New in Neurosurgery?
page 27


13:30-17:00
EEG Course
page 28

13:30-17:00
Dementia Course
page 28

13:30-17:00
MS Course
page 29

13:30-17:00
What's New in Neurology?
page 30

13:30-17:00
Neuromuscular Course
page 31



Booth Assignments

Bayer Healthcare	1
Biogen Idec Canada	20
Boehringer Ingelheim	31
Bristol Myers Squibb / sanofi-aventis	8
Canada Microsurgical Ltd	12
Carl Zeiss Canada	24
Codman/Johnson & Johnson	3
Galen Medical Ltd.	27
Janssen-Ortho Inc	16
Leica Microsystems	11
Medtronic of Canada Ltd	37
Merck Frosst Canada Ltd	22
Novartis	6
Novo Nordisk Canada Inc	26
Pfizer Canada	14
Prestwick Pharmaceuticals Canada	25
Hoffman LaRoche	19
Roxon Medi-Tech Ltd	36
Talecris Biotherapeutics	18
Teva Neuroscience	30
Valeant Canada Ltd	13
XLTEK	10

Due to space constraints, the following requested but were not provided exhibiting opportunities:

- Grass Technologies
- Karl Storz Endoscopy Canada
- Kyphon Inc.
- Stellate
- Stryker Canada
- Summit Technologies

A new feature of the Congress; we are presenting posters digitally this year. Please take note of the station locations on the Exhibition Hall floorplan. Each station contains abstracts organized by category for easy reference. Please take a moment to visit these stations and tour the Exhibit Hall.

GENERAL MEETING INFORMATION

MEETING LOCATION AND REGISTRATION

Meeting Site

Shaw Conference Centre
9797 Jasper Avenue
Edmonton, Alberta T5J 1N4

Delegate & Exhibitor Registration – On Site

Registration Desk

Shaw Conference Centre

Tuesday, June 19	07:30 – 18:30
Wednesday, June 20	07:00 – 18:30
Thursday, June 21	07:00 – 18:30
Friday, June 22	07:00 – 13:30

FUTURE MEETINGS OF THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

June 17 – 20, 2008	Victoria, British Columbia
June 9 – 12, 2009	Halifax, Nova Scotia
June 8 – 11, 2010	Quebec City, Quebec

QUESTIONS?

Advance Group

Attention: Canadian Neurological Sciences Federation
Suite 101 - 1444 Alberni Street
Vancouver, BC, Canada V6G 2Z4
Phone: +1-604-688-9655 (Extension 2)
1-800-555-1099 (Extension 2)
Fax: +1-604-685-3521
E-mail: cnsfinfo@advance-group.com

Registration Details

Full Registration

- Full registrants can attend all sessions of the 2007 Annual Congress from Tuesday, June 19 through Friday, June 22.
- Includes the Exhibitors' Reception and the Presidents' Reception on Wednesday, June 20 and the Presidents' Dinner on Thursday June 21, plus lunch in the Exhibit Hall on Thursday and Friday.

One-Day Registration

- One-day registrants can attend scientific sessions only, on one of Tuesday, Wednesday, Thursday or Friday.
- Does not include the Presidents' Reception, or the Presidents' Dinner, but tickets are available for purchase for these events.

Badges

- Delegates must wear their badges at all times to gain entry to Congress Courses, Scientific Sessions and evening events. Tickets will be collected for the Presidents' Reception and the Presidents' Dinner for those who have purchased extra tickets.

Registration Forms

- You can register online at www.cnsfederation.org, or the forms can be also mailed or faxed to:

Advance Group Conference Management
Suite 101 - 1444 Alberni Street
Vancouver, BC, Canada V6G 2Z4
Fax: +1-604-685-3521



ACCOMMODATION INFORMATION

Support your Federation by booking your hotel stay with a CNSF partner hotel and receive a reduced rate! The Advance Group has been assigned as the Official Housing Bureau for the 42nd Congress of the Canadian Neurological Sciences Federation to be held in Edmonton, Alberta, June 19 - 22nd, 2007. Please be sure to take advantage of the special hotel rates available only to the Congress delegates.

Preferential Rates

The CNSF has a block of rooms reserved and has established preferential rates for conference delegates at the following hotels:

Fairmont MacDonald

Single or Double	\$199
View Room	\$219
Deluxe Room	\$239
Deluxe View	\$259

3rd and 4th person add \$20.00/person/night to room type above.

Westin

Single or Double	\$165
------------------	-------

3rd and 4th person add \$25.00/person/night to room type above.

Booking Hotels

- Reservations process: The Advance Group accepts hotel requests online at www.cnsfederation.org or in writing via fax (604-685-3521) or mail using the CNSF Hotel Reservation Form. Reservations will not be accepted by telephone.
- Hotel enquiries, questions or any group request of 10 rooms or more, can be sent to the following email address: cnsf2007@advance-group.com.
- Hotel reservations will be assigned on the information received and on a first come, first served basis, based on the hotel and room availability.
- Individual Reservations: Each room requested does require a one night deposit to confirm, payable either by credit card or cheque/money order made payable to the Advance Group. This cheque or money order (CANADIAN FUNDS) must accompany the hotel form in order for your reservation to be processed. Please submit one form for each room reservation.
- Hotel confirmations are forwarded directly to you via email, fax or mail.
- Hotel Cancellation: Cancellations made within 48 hours prior to arrival will be charged a one-night penalty by the hotel.
- All hotel prices are quoted in Canadian dollars, per room, per night. Rates are subject to an additional 4% hotel tax, 6% GST and 1% Tourism Levy. Visitors residing outside of Canada are eligible for a GST rebate on the guest room portion of their bill. GST rebate forms are available for you at your hotel when checking out.

SOCIAL EVENTS

Exhibitors' Reception

Wednesday, June 20, 2007 - 17:30-19:00

Shaw Conference Centre - Meeting level-exhibit area

Wine & Cheese. Cash bar. **Must have badges for entry.**

Presidents' Reception

Wednesday, June 20, 2007 - 19:00-21:00

Empire Ballroom, Fairmont MacDonald

Business attire - Refreshments and hors d'oeuvres. 2 complimentary drink tickets, then cash bar. **Part of package for full registrants, tickets will be issued and collected at door.** Extra tickets are also available for purchase at \$30 each (plus tax).

Residents' Soirée

Thursday, June 21, 2007 - 18:00-19:00

Shaw Conference Centre Salon 5/6

All residents are invited to meet and mingle with their colleagues and CNSF board members. Includes complimentary beverages.

Presidents' Dinner

Thursday, June 21, 2007 - 19:00

Shaw Conference Centre - Hall D on the Pedway Level

Business attire. Four course dinner, entertainment. This dinner is part of the full conference registration. Your badge will be required to enter. For those who purchased extra tickets, they will be collected at the door. Extra tickets are available for purchase at \$75 each (plus tax).

HOW TO OBTAIN CME CREDITS / HOURS

MAINTENANCE OF CERTIFICATION / MAINTIEN DU CERTIFICAT

The 42nd Annual Congress of the Canadian Neurological Sciences Federation is an accredited learning activity approved by the CNS and the CNSS, as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The Royal College of Physicians and Surgeons of Canada established the Maintenance of Certification program on January 1, 2001. Participation in this program is a requirement for admission to and renewal of Fellowship and for the use of the designations FRCPC and FRCSC.

The 2007 Congress has been approved for Section 1 under the Maintenance of Certification program. This means each attendee is assigned one credit per hour in education sessions. Breaks, lunch, and the poster sessions are excluded.

As Fellows are responsible for keeping track of their hours of participation in educational activities, they should keep a copy of this meeting program and their registration form for future reference. Certificate of Attendance Forms will only be issued once you have completed the Overall Congress Evaluation on line through a link we will be providing to all delegates, or completed the hard copy we will have in the delegates portfolio distributed at the Congress and faxed it to the CNSF Secretariat at 1-403-229-1661. The deadline for completion and submission is June 30th, 2007.

For more information about the Maintenance of Certification Program, please refer to the Royal College website <http://www.rcpsc.medical.org> or e-mail the CNSF secretariat office at info@cnsfederation.org

Le 42ème congrès annuel de la Fédération des sciences neurologiques du Canada est une activité éducative agréée, approuvée par la SNC et la SCNCH selon la définition du programme de maintien du certificat du Collège royal des médecins et chirurgiens du Canada.

Le Collège royal des médecins et chirurgiens du Canada a institué le maintien du certificat le 1er janvier 2001.

Participer à ce programme est obligatoire pour l'obtention ou le renouvellement du titre d'Associé et pour utiliser les mentions FRCPC et FRCSC.

Le congrès 2007 a été approuvé comme activité de la Section 1 du programme de maintien du certificat. Ce qui veut dire que chaque participant reçoit un crédit pour chaque heure de séance éducative. Les pauses, les déjeuners et les présentations affichées n'en font pas partie.

Comme c'est la responsabilité des Associés de tenir une comptabilité de leurs heures de participation aux activités de formation, ils doivent garder une copie du programme de ce congrès et le formulaire d'inscription en vue d'une utilisation ultérieure. Des attestations d'assiduité ne vous seront délivrées que lorsque vous aurez rempli en ligne l'évaluation générale du congrès en utilisant un lien que nous indiquerons à tous les délégués, ou bien lorsque vous aurez rempli la feuille que vous trouverez dans le cartable distribué à tous les délégués au congrès et que vous l'aurez envoyée par télécopie au secrétariat de la FSNC au 1-403-229-1661.

Date-limite pour remplir et soumettre l'évaluation: 30 juin 2007.

Pour plus de renseignements sur le programme de maintien du certificat, veuillez consulter le site web du Collège royal à <http://www.rcpsc.medical.org> ou envoyer un courriel au secrétariat de la FSNC à info@cnsfederation.org

CME HOURS *Breaks, lunch and poster sessions are excluded*

Date: Tuesday, June 19, 2007

Neurobiology Review Course	7.5
ALS Strategies for Quality of Life/Quality Care	7.0
Child Neurology Day-Controversies and Advances in Neonatal Neurology	6.5
Epilepsy Video Session	2.0
Movement Disorders Management: Drugs to Surgery	2.0

Date: Wednesday, June 20, 2007

Grand Opening Plenary: Scientific and Technical Advances in the Clinical Neurosciences	2.0
Chair's Select Plenary Presentation	1.5
Neuropathic Pain - Pathophysiology, Prevention and Management	3.0
Spine Course - The Triage and Management of the Cervical Spondylotic Myelopathy Patient	3.0
Clinical Electromyography Course	3.5
Stroke Course	3.0
Epilepsy Course: Intractable Epilepsy	3.0
Neurocritical Care Course	3.5

Date: Thursday, June 21, 2007

Plenary Session: CNS, CACN and CSCN Neurology	1.5
Plenary Session: CNSS Neurosurgery	1.5
Platform Sessions - Morning	2.0
Platform Sessions - Afternoon	2.5

Date: Friday, June 22, 2007

Distinguished Guest Lecturer	1.0
Grand Rounds	1.5
Headache Course	3.5
What's New in Neurosurgery Course	3.5
EEG Course	3.5
Dementia Course	3.0
MS Course	3.5
What's New in Neurology	3.5
Neuromuscular Course	3.0

Total CME Hours 81.0

Anthony A. Amato

Anthony A. Amato, M.D. graduated Magna Cum Laude with a B.S. degree at Case Western Reserve University in 1982 and had a fully paid scholarship (US Air Force) for medical school at the University of Cincinnati where he obtained his M.D. degree in 1986. He did his internal medicine internship and neurology residency at Wilford Hall Medical Center (WHMC) in San Antonio and his neuromuscular fellowship Ohio State University with Jerry Mendell, M.D. Dr. Amato returned to WHMC as the Chief of the Neuromuscular Division from 1992-1996. After fulfilling his military obligation he joined the Department of Neurology at the University of Texas Health Science Center at San Antonio where he was co-Director of the Neuromuscular Service.

In August 1999 following a national search he was recruited to Brigham and Women's Hospital (BWH) to be the Chief of the Neuromuscular Division and Director of the Clinical Neurophysiology Laboratory with an appointment as Associate Professor of Neurology at Harvard Medical School. He is now the vice-chairman of the Department of Neurology at BWH. He initiated and directed the integrated BWH-MGH Clinical Neurophysiology Fellowship program which is ACGME. In 2006, he started an ACGME-approved Neuromuscular Medicine Fellowship (6 new fellows per year) that encompasses BWH, MGH and Children's Hospital.

Dr. Amato has been a principle investigator or co-investigator in many clinical trials sponsored by the NIH, FDA, or industry in various neuromuscular disorders. He is a founding member of the Muscle Study Group, a consortium of scientific investigators from academic and research centers who are committed to the cooperative planning, implementation, analysis and reporting of controlled clinical trials and of other research for muscle and other neuromuscular diseases. The MSG aims to advance knowledge about the cause(s), pathogenesis, epidemiology, and clinical manifestations of muscle disease and related neuromuscular disorders and to develop and implement strategies to examine promising therapeutic interventions.

Dr. Amato is a grant reviewer for the NIH and The Myositis Association. He is a member of the Data and Safety Monitoring Board (DSMB) for all gene therapy trials for the National Heart, Lung and Blood Institute and also a member of the DSMB for the Familial Amyloid Polyneuropathy Trial for NINDS/NIH. He is Associate Editor for Muscle & Nerve. He has authored or co-authored 91 journal articles, 45 book chapters, and 2 books.



Amin B. Kassam

Amin Kassam, MD, completed his medical and undergraduate education at the University of Toronto and his residency and fellowship training at the University of Ottawa. Dr. Kassam pursued additional post-graduate training in epidemiology and clinical outcomes. Dr. Kassam joined the faculty of the Department of Neurological Surgery at the University of Pittsburgh in February of 1998. He spent the next year focusing on microvascular surgery. Dr. Kassam has performed over 1,000



microvascular decompression procedures for cranial nerve neuropathy and has provided a unique perspective by using the endoscope to visualize and enhance difficult regions. Since his appointment, he has also focused on building a collaborative center to provide comprehensive care for complex pathology of the skull base. This center builds on the strength of combining the talents of surgeons from multiple specialties. This allows for the use of proven conventional approaches in conjunction with new minimally invasive endoscopic approaches to provide safe and effective treatment for patients. This has culminated in the development of the multidisciplinary Minimally Invasive Neurosurgical Center (MINC). Dr. Kassam along with Carl Snyderman, MD, and Ricardo Carrau, MD, were directly involved with the development of the Expanded Endonasal Approach (EEA). This approach represents an entirely new paradigm to remove complex lesions of the skull base and brain without incisions. The center, under the direction of Dr. Kassam, has pioneered and developed much of the technology and instrumentation used during the EEA surgeries. With continued research and experience, he now uses the EEA surgery for most tumors affecting the skull base. Dr. Kassam has performed over 3,000 neurosurgical procedures including over 700 minimally invasive endoscopic procedures. Dr. Kassam remains active in cerebrovascular surgery and has helped to develop a program to better understand the genetic alterations that lead to the development of intracranial aneurysms.

In July 2006, Dr. Kassam was named Interim Chairman of the Department of Neurological Surgery. Since then he has focused on increasing interdisciplinary activities between neurosurgery and radiology, medical, radiation and surgical oncology, anesthesiology, neurology, and otolaryngology. It is hoped that these cooperative ventures will lead to new innovations in care for patients with a variety of neurologic abnormalities. Dr. Kassam has over 80 peer reviewed publications, an additional 11 book chapters currently published or in press, and is funded by both industry and the NIH. He lectures extensively nationally and internationally on surgery of the cranial nerves, skull base and on minimally invasive endoscopic techniques.

Walter Kucharczyk

Walter Kucharczyk was born, raised and educated in Toronto. He graduated from the University of Toronto's Faculty of Medicine in 1979, after which he undertook specialty training in Radiology in Toronto, followed by subspecialty training in Neuroradiology and Magnetic Resonance Imaging at the University of California, San Francisco from 1984 to 1986. He returned to a faculty position at the University of Toronto in 1986, and became the inaugural Director of Magnetic Resonance Imaging at what was then the Toronto General Hospital. He has remained Director of MRI ever since. At the University, he became Professor and Chair of the Department of Medical Imaging in 1991, a position he has held until today. He is Past-President of the International Society of Magnetic Resonance in Medicine (ISMRM), the largest research and education group in the world (5000 members) devoted to developing and teaching magnetic resonance to doctors and scientists.

During the past 10 years, Dr. Kucharczyk's research has focused on developing and applying modern high-speed 3D imaging technologies for non-invasive and minimally invasive treatment. He has been awarded several multi-million dollar grants from Technology Ontario (the predecessor of



PLENARY GUEST SPEAKERS

ORDCF), the Canadian Foundation for Innovation, the Ontario Research and Development Challenge Fund (CFI), and most recently, the Leading Edge Fund of CFI. Starting in 1997, he has worked closely with key UHN co-investigators, especially Dr. Mark Bernstein in Neurosurgery and Dr. John Trachtenburg in Urology, to bring these innovative methods to the patient.

Dr. Kucharczyk has led the Toronto University Health Network in a multidisciplinary, multi-institutional, \$33M CFI grant (Functional Imaging Research Network) that has been a foundation for MRI research and image guidance therapy research at UHN for the past 7 years. In a related program, he has also been PI and co-led a \$26M ORDCF grant for the Ontario Consortium of Image Guided Therapy and Surgery (OCITS). He is one of three provincial leaders in the OCITS consortium. Two years ago he became a Project Leader of the UHN "Guided Therapeutics" Programme and co-leader of the new \$25M UHN initiative "The operating room of the future" in which image-guided therapy will play a prominent role.

He published several of the early papers on the design, operation, and treatment of novel Interventional MRI systems to guide conventional "open" surgical procedures, as well as research-based novel percutaneous and transcutaneous heat ablative systems. He published several of the early papers on MR thermometry to monitor, in a spatially localized manner, the effects of heat ablation on human cancer in vivo, including the only publications in the world on microwave ablation with MR thermometry for the treatment of recurrent prostate cancer.

Stephen Ashwal

Dr. Stephen Ashwal is Distinguished Professor and Chief of the Division of Child Neurology in the Department of Pediatrics at Loma Linda University School of Medicine. He is a graduate of New York University School of Medicine (1966-70), and completed his residency training programs in Pediatrics (Bellevue Hospital, 70-73) and in Child Neurology (University of Minnesota, 73-76). His research activities have focused on critical care issues in child neurology related to brain death, the vegetative and minimally conscious states, bacterial meningitis, and near drowning; the role of nitric oxide in focal cerebral ischemia; development of animal models of neonatal stroke and the use of proton

spectroscopy for outcome prediction after acute CNS injuries. He has been a member of the Child Neurology Society since 1975 and served as chair of the Scientific Selection, Ethics, Archives and Practice Committee, Councilor from the West, Secretary-Treasurer of the Society, and President (2001-03). Dr. Ashwal edited *The Founders of Child Neurology*, published on behalf of the Society in 1990, that is a history of the field of child neurology and its major contributors. He served as co-chair (representing the CNS) on The Multi-Society Task Force on the Persistent Vegetative State. He has been active in the development of practice parameters related to child neurology and served as a member of the Quality Standard Subcommittee of the

American Academy of Neurology that is responsible for development of guidelines dealing with issues related to the evaluation of children with autism, cerebral palsy, developmental delay, headaches and status epilepticus. With Dr. Kenneth Swaiman and Dr. Donna Ferriero, he served as coeditor of one of the main textbooks in the field of child neurology, *Pediatric Neurology: Principles & Practice* (2006).

Michael Shevell

Dr. Shevell is a pediatric neurologist at the Montreal Children's Hospital and a Professor (with Tenure) in the Departments of Neurology/Neurosurgery and Pediatrics at McGill University. He holds a subspecialty certification in neurodevelopmental disabilities. A former Chercheur Boursier Clinicien of the FRSQ he has an active research program focusing on issues related to neonatal neurology, children with or at risk for neurodevelopmental sequelae, in particular cerebral palsy, global developmental delay and developmental language impairment. He has presently over 130 publications and 40 book chapters/invited papers. He currently serves on four editorial boards (Canadian Journal of Neurological Sciences, Pediatric Neurology, Journal of Child Neurology and Seminars in Pediatric Neurology). He was the lead author on the American Academy of Neurology/Child Neurology Society Practice Parameter on global developmental delay. He is currently Director of the Quebec Cerebral Palsy Registry. A former President of

Canadian Association of Child Neurology he presently serves on the Executive Board of the International Child Neurology Association and has been Chair of the Ethics Committee of the Child Neurology Society for the past decade. He was Chairman of the recent Xth World Congress of the International Child Neurology Association held in Montreal in June 2006.



Andres M. Lozano

Dr. Lozano obtained his MD degree from the University of Ottawa and his PhD in Neurobiology from McGill University. He was appointed to the neurosurgical faculty at the University of Toronto in 1991 and became full Professor in 1999. He is currently Professor and RR Tasker Chair in Functional Neurosurgery and holds a Canada Research Chair in Neuroscience at the University of Toronto.

Dr. Lozano's research is focused on understanding the cellular pathogenesis and developing novel treatments, including surgical therapies for neurological and psychiatric disorders such as Parkinson's disease, dystonia and depression. His work has appeared in over 250 peer-reviewed publications and he has been invited lecturer or visiting professor throughout the world. He serves on the board and executive of several international organizations and is currently President of the World Society for Stereotactic and Functional Neurosurgery, and Chairman of the Stereotactic and Functional Neurosurgery Section of the World Federation of Neurosurgical Societies. He serves the international editorial board of ten journals and has received a number of awards including the Gold Medal of the Royal College of Physicians and Surgeons of Canada and the Penfield Award.



Michael Bliss

Michael Bliss held the elite title of University Professor when he retired in 2006 after a long career at the University of Toronto. Formally University Professor Emeritus, he is an independent scholar and writer, based in Toronto and Prince Edward Island. He specializes in the history of medicine and the history of Canada.



His twelve books (including *A Canadian Millionaire*, *The Discovery of Insulin*, *Banting*, *Northern Enterprise*, *Plague*, *Right Honourable Men*, *William Osler*, *A Life in Medicine*, and *Harvey Cushing: A Life in Surgery*) have received numerous honours, including all the major prizes awarded by the Canadian Historical Association, two City of Toronto Book Awards, two Jason Hannah Medals for medical history from the Royal Society of Canada, the Welch Medal of the American Association for the History of Medicine, and the National Business Book Award.

Professor Bliss was appointed a Member of the Order of Canada in 1999, and elected a Fellow of the Royal Society of Canada in 1984. The Royal Society awarded him its Tyrrell Medal in 1988 "for outstanding work in the history of Canada". At the time of his retirement, *Maclean's*, Canada's national newsmagazine, referred to him as "perhaps Canada's greatest living historian."

Michael Bliss was born in 1941, married in 1963, and has three children. He has been awarded Honorary Doctor of Letters degrees from McGill University and McMaster University and is an Honorary Fellow of the Royal College of Physicians and Surgeons of Canada.

Charles Haw

Charles Haw is an assistant professor in the Department of Surgery, Division of Neurosurgery, University of British Columbia. He completed his medical school and residency training at the University of British Columbia. Subsequently, he travelled to Toronto where he had two and a half years training in interventional neuroradiology. Currently he performs fairly general neurosurgery with a heavy concentration in the surgical and endovascular management of vascular disorders. While he enjoys treating dural fistulas, which will be the topic of his lecture, he realizes that life does not start and end in a shunting zone.



Educational Objectives for the 2007 Congress:

By the end of the Congress the participants will be able to:

- **Discuss the advances in the diagnosis and management of acute and chronic neurological diseases**
- **Review new treatment options for neurosurgical illnesses**
- **Explore advances in neurobiology**
- **Assess the consequences of neurological injury in the newborn**

Dedication

Leadership

Support


Boehringer Ingelheim (Canada) Ltd. proudly supports the Canadian Neurological Sciences Federation Annual Congress as a Platinum Sponsor.

Boehringer Ingelheim (Canada) Ltd. is committed to cerebrovascular and cardiovascular protection research.



Boehringer
Ingelheim

SALON/MEETING LEVEL MAP



Our Vision:

**With passion, purpose and partnerships,
we transform scientific discoveries into
advances in human healthcare.**



**As a platinum sponsor,
Biogen Idec Canada is
proud to support the
2007 Congress of the
Canadian Neurological
Sciences Federation**

Neurobiology Review Course

Salon 4 - 08:00-17:00

Course generously supported through an unrestricted educational grant from the Canadian Neurological Society Foundation.

Chair: Jack Jhamandas

Learning Objectives: At the completion of this symposium, participants will be able to:

1. Describe the neurobiology of neurodegenerative disease.
2. Reflect upon the neural basis for rhythmic behaviour in the CNS
3. Articulate the neuroimmunology and neuroimaging of Multiple Sclerosis
4. Review the mechanisms and pathophysiology of epilepsy

Target Audience: Clinicians from allied Neuroscience disciplines (neurologists, neurosurgeons, neurophysiologists, etc.) and trainees (residents, fellows, etc.)

FUNDAMENTAL MECHANISMS OF NEURODEGENERATIVE DISEASES

- 08:00 **Neurobiology of the Prion Protein Family**David Westaway, (Edmonton, AB)
 08:45 **Molecular Basis of Memory Loss in Transgenic Models of Alzheimer's Disease**.....Karen Hsiao Ashe, (Minnesota, USA)
 09:30 Discussion
 09:45 Break

NEURAL BASIS FOR RHYTHMIC BEHAVIOR IN THE CNS

- 10:00 **Central Control of Respiratory Rythmogenesis**.....John Greer, (Edmonton, AB)
 10:45 **Recent Advances in the Neurobiology of Walking**Keir Pearson, (Edmonton, AB)
 11:30 Discussion
 12:00 Lunch break

UPDATE ON NEUROIMMUNOLOGY AND NEUROIMAGING OF MULTIPLE SCLEROSIS

- 13:15 **Autoimmunity in Multiple Sclerosis: A double-edged sword**.....Fabrizio Giuliani, (Edmonton, AB)
 14:00 **MRI Based Biomarkers of Pathology in Multiple Sclerosis**.....Ross Mitchell, (Calgary, AB)
 14:45 Discussion

EPILEPSY: INSIGHTS INTO PATHOPHYSIOLOGY

- 15:00 **Studying the functional anatomy of the limbic system through temporal lobe epilepsy and magnetic resonance imaging**Don Gross, (Edmonton, AB)
 15:45 **Mechanisms of Epilepsy**William Colmers, (Edmonton, AB)
 16:30 Discussion and evaluation

ALS Strategies for Quality of Life/Quality Care

Salon 3 - 08:30-17:00

Chair: David Cameron, Cathy Martin

Learning Objectives: At the completion of this symposium participants will be able to:

1. Describe the current clinical and pathophysiological features of ALS.
2. Identify and apply strategies to improve the function and quality of life for people with ALS.
3. Demonstrate an understanding of research initiatives and findings in ALS.

Target Audience: Interactive full day sessions with patients, caregivers, allied health professionals, neurologists, physiatrists, community support agencies: a comprehensive review of current topics in ALS including diagnosis and research, management and advocacy.

08:30 Registration

09:00 Welcome.....David Cameron, (Toronto, ON); Cathy Martin, (Edmonton, AB)

SESSION I PLENARY PRESENTATION - CHAIRS: COLLEEN O'CONNELL, SANJAY KALRA

09:10 **Update - Advances in clinical care**Michael Strong, (London, ON)

09:35 **Update - Advances in basic science**Denise Figlewicz, (Toronto, ON)

10:00 Question and answer session

10:20 Break

SESSION II PANEL PRESENTATION - CHAIR: TESSA GORDON

10:40 **Patient Perspective**TBC

11:00 **ALS Society of Alberta**TBC

11:20 **Environmental risk factors**Chris White, (Calgary, AB)

11:40 **Managing excessive saliva: drugs, botox, radiation**Stuart Cleary, (Edmonton, AB)

12:00 Question and answer session

12:15 Lunch break

SESSION III BREAKOUT SESSIONS

13:30 **Patients, Caregivers and Healthcare Professionals** - Moderator: Mary Hatcher

(1) **Advanced directives**Melinda Hatfield, SW and Jane Rivest, (Calgary, AB)

(2) **Is there value in home visits and telehealth?**Pat Carey, (Edmonton, AB)

(3) **Sexuality**Colleen O'Connell, (Fredericton, NB)

13:30 **Physicians and Researchers** - Moderator: Tim Doherty

(1) **The role of EMG, MUNE and transcranial magnetic stimulation in diagnosis, follow-up and clinical trials**Ming Chan, (Edmonton, AB)

(2) **Symptoms management**Sanjay Kalra, (Edmonton, AB)

15:00 Break

SESSION IV - CHAIRS: DAVID CAMERON, MARY HATCHER

15:15 **Discussing hope with ALS patients and families**Wendy Johnston, (Edmonton, AB)

15:55 **Concluding remarks and completion of evaluation forms**David Cameron, (Toronto, ON); Mary Hatcher, (Halifax, NS)

17:00 Discussion and evaluation

Child Neurology Day - Controversies and Advances in Neonatal Neurology

Salon 2 - 08:30-17:00

Chair: Jerome Yager, Steve Miller

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. List the common causes of neurologic injury in the newborn
 2. Describe the neurologic consequences of congenital heart disease, and an understanding of newer techniques of detection
 3. Understand causes and outcomes of premature birth
 4. Articulate new approaches to therapeutic intervention for the brain injured newborn

Target Audience: Pediatric neurologists, pediatricians, neonatologists, residents, nurses.

08:30	Introduction
08:40	Neonatal brain ischemia: Neuroimaging as a basis for rational stem cell therapyStephen Ashwal, (Loma Linda, CA, USA)
09:40	Neonatal seizures - Do they cause brain damage?Lionel Carmant, (Montreal, QC)
10:20	Break
10:50	State of the art neuroimaging and the newborn brainSteve Miller, (Vancouver, BC)
11:30	A new look at outcomes of infants with congenital heart diseaseAnnette Majnemer, (Montreal, QC)
12:10	Lunch
13:30	Does inflammation matter?Guillaume Sebire, (Sherbrooke, QC)
14:10	Outcomes in the extremely preterm infant: What's new and where are we going?Charlene Robertson, (Edmonton, AB)
14:50	Therapeutic interventions for the newborn: Do we have anything to offer?Jerome Yager, (Edmonton, AB)
15:40	Break
16:00	Case reports
16:30	Discussion and evaluation

Epilepsy Video Session

Salon 4 - 18:00-20:00

Chair: Richard McLachlan

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Understand how to best utilize videos to diagnose paroxysmal events
 2. Explore the electro-clinical features of neuro-metabolic seizures
 3. Review the use of videos in the pediatric population

Target Audience: Residents, fellows and students. Adult and pediatric neurologists, neurology nurses and EEG technologists.

18:00	Electroclinical features of neurometabolic causes of epilepsy	Mary Connolly, (Vancouver, BC)
18:15	Discussion	
18:25	Epilepsy in the land of milk and honey	Sam Wiebe, (Calgary, AB)
18:45	Discussion	
18:55	Pediatric epilepsy	Sharon Whiting, (Ottawa, ON)
19:15	Discussion	
19:25	Something of interest to everyone	Richard McLachlan, (London, ON)
19:55	Discussion and evaluation	

Movement Disorders Management: Drugs to Surgery

Wedgewood Fairmont - 18:00-20:00

Course generously supported through an unrestricted educational grant from Prestwick Pharma.

Chair: Richard Camicioli

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Understand the available evidence based approaches to the treatment of Parkinson's disease
 2. Identify candidates for surgical assessment for parkinsonism and hyperkinetic movement disorders and be aware of realistic outcomes and risks
 3. Review the evidence based treatment for chorea, dyskinesia and dystonia

Target Audience: TBC

18:00	Medical management of Parkinsonism	Oksana Suchowersky, (Calgary, AB)
18:25	Surgical management of Parkinsonism	Christopher Honey, (Vancouver, BC)
18:55	Medical management of Chorea and Dystonia	Mandar Jog, (London, ON)
19:25	Surgery of hyperkinetic movement disorders	Andres Lozano, (Toronto, ON)
19:55	Discussion and evaluation	

SPECIAL INTEREST GROUPS

18:00-20:00

18:00	ALS	Jasper Room Fairmont	Angela Genge
18:00	NEUROMUSCULAR	Salon 3	Mike Nicolle
18:00	NEUROSURGERY RESIDENTS' EDUCATION	Drawing Room Fairmont	Brian Toyota
18:00	UNDERGRADUATE NEUROLOGICAL EDUCATION	Salon 13 & 14	Kevin Busche

Grand Opening Plenary: Scientific and Technical Advances in the Clinical Neurosciences

Salon 12 -

08:30-10:30

Chairs: Mark Hamilton, Andrew Kirk

Learning Objectives: At the completion of this symposium, participants will be able to:

1. Discuss contemporary imaging techniques in neurological disorders
2. Articulate neurosurgical treatment options for psychiatric disorders
3. Describe the utilization of advanced neuron-imaging techniques for pediatric traumatic brain injury

08:30 Welcome and Introduction

08:45 **Contemporary imaging techniques in neurological disorders**.....Walter Kucharczyk, (Toronto, ON)*

09:20 **Contemporary neurosurgical approaches to the treatment of psychiatric disorders**.....Andres Lozano, (Toronto, ON)*

09:55 **Tibbles Lecture - Pediatric traumatic brain injury: Normal appearing brain is not normal - Use of advanced neuroimaging techniques**Steve Ashwal, (Loma Linda, CA, USA)*

* Sponsored by the Royal College of Physicians and Surgeons of Canada.

Chair's Select Plenary Presentation

Salon 12 - 10:45-12:15

Neuropathic Pain - Pathophysiology, Prevention and Management

Drawing Room Fairmont - 14:00-17:30

Course generously supported through an unrestricted educational grant from Pfizer Inc.

Chair: Dwight Moulin

Learning Objectives: At the completion of this symposium, participants will be able to:

1. Understand the pathophysiology of neuropathic pain as a basis for treatment
2. Provide an evidence based approach to the management of neuropathic pain
3. Appreciate the value of novel agents in the prevention and management of neuropathic pain

Target Audience: Family doctors, neurologists, neurosurgeons and clinical nurse practitioners.

14:00 **Prevalance and pathophysiology of neuropathic pain**Dwight Moulin, (London, ON)

14:30 Discussion

14:45 **Post-herpetic neuralgia - assessment and management**.....Peter Watson, (Toronto, ON)

15:15 Discussion

15:30 Nutrition Break

15:45 **Evidence-based guidelines for the management of neuropathic pain**Dwight Moulin, (London, ON)

16:30 **Novel agents in the management of neuropathic pain - cannabinoids and beyond**John Clark, (Calgary, AB)

17:00 Discussion and evaluation

Spine Course - The Triage and Management of the Cervical Spondylotic Myelopathy Patient

Wedgewood Fairmont - 14:00-17:30

Chair: Eric Massicotte

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Appreciate and understand the challenges of assessing the patients with myelopathy. List clues that can assist in the accurate diagnosis
 2. Discuss management options in this patient population
 3. Review specific surgical approaches for the spondylitic patients
 4. Articulate the role of minimally invasive and reconstructive techniques in this patient population

Target Audience: Neurologists and neurosurgeons both in training and in established practices along with health care providers can benefit from this session.

14:00	Diagnostic challenges: What are the clinical clues?	Robert Chen, (Toronto, ON)
14:15	Discussion	
14:30	Natural history of spondylosis and myelopathy	Richard Fox, (Edmonton, AB)
14:45	Discussion	
15:00	Anterior approaches to cervical spondylosis	Steve Casha, (Calgary, AB)
15:15	Discussion	
15:30	Posterior approaches to cervical spondylosis	Ramesh Sahjpaul, (Vancouver, BC)
15:45	Discussion	
16:00	Break	
16:15	Role of minimally invasive techniques	Sean Christie, (Halifax, NS)
16:30	Discussion	
16:45	Complex reconstruction strategies	Eric Massicotte, (Toronto, ON)
17:00	Functional outcome of cervical spondylotic myelopathy	Sukhuinder Kalsi-Ryan, (Toronto, ON)
17:10	Discussion and evaluation	

Clinical Electromyography Course*(See below for rooms) - 14:00-17:30**Course generously supported through an unrestricted educational grant from Roxon Medi-Tech and XLTEK.*

Workshop 1, 2, and 4 will be held at the Shaw Centre. Workshop 3 will be held at the University of Alberta
[No transportation provided]. There will be 2 sessions of 1, 2, and 4 only.

Chairs: Ming Chan, Joseph Chu

Learning Objectives: At the completion of this symposium, participants will be able to:

1. Understand the electrodiagnostic approach to ALS and look-alikes
2. Review the single fiber EMG
3. Describe the electrodiagnostic tests and identification of uncommonly studied nerves of the upper extremity
4. Discuss the EMG pearls and pitfalls especially when studying unusual muscles

Target Audience: Neurologists, EMGers, neurology fellows and residents, physiologists and EMG technicians.

14:00 &
 16:00 **Workshop I: Electrodiagnostic approach in the work-up of ALS and look-alikes** **Salon 15** Chris White, (Calgary, AB)
 14:00 &
 16:00 **Workshop II: Single fibre EMG** **Salon 16** Michael Nicolle, (London, ON)
 14:00 **Workshop III: Anatomic identification and electrodiagnostic testing of uncommonly studied nerves in the upper limb**
 **University of Alberta** Lalith Satkunam, (Edmonton, AB); Ian Grant, (Halifax, NS); Michael Morhart, (Edmonton, AB)
 14:00 &
 16:00 **Workshop IV: EMG of unusual muscles and their relevance to electrodiagnosis in neurology**
 **Salon 19** Jasper Daube, (Rochester, MN, USA)

Stroke Course**Salon 2 - 14:00-17:30***Course generously supported through an unrestricted educational grant from Sanofi-aventis/Bristol-Myers Squibb.***Chairs:** Khurshid Khan, Ashfaq Shuaib

Learning Objectives: At the completion of this symposium, participants will be able to:

1. Analyze the pathophysiological mechanisms contributing to atherosclerosis and various types of stroke
2. Explore in detail the various new imaging technologies that help a diagnosis in stroke
3. Identify the best treatment options for specific stroke sub-types
4. Critically assess new emerging therapies in cerebral vascular disease

Target Audience: Neurologists, neurosurgeons and other health care professionals involved in the treatment of patients with cerebrovascular disease.

14:00 **Acute stroke management** Philip Teal, (Vancouver, BC)
 14:25 Discussion
 14:35 **Stroke prevention** Ashfaq Shuaib, (Edmonton, AB)
 15:00 Discussion
 15:10 **Neuroimaging (CT/MRI) in acute stroke** Ken Butcher, (Edmonton, AB)
 15:35 Discussion
 15:40 Break
 15:50 **Intracerebral hemorrhage** Matthew Hogan, (Ottawa, ON)
 16:15 Discussion
 16:25 **Neurosurgical approach to "asymptomatic" cerebrovascular conditions (including carotid disease, aneurysms and vascular malformations)** Max Findley, (Edmonton, AB)
 16:50 Discussion
 17:00 **Endovascular procedures** Michael Chow, (Edmonton, AB)
 17:25 Discussion and evaluation

Epilepsy Course: Intractable Epilepsy

Jasper Room Fairmont - 14:00-17:30

Chair: Richard Wennberg

Learning Objectives: At the completion of this symposium, participants will be able to:

1. Identify patients with intractable epilepsy
2. Assess the burden of intractable epilepsy in Canada
3. Understand when and why to refer patients to specialized epilepsy centers
4. Understand the pre-surgical investigations and outcomes of epilepsy surgery in children and adults

Target Audience: Adult and pediatric neurologists and neurosurgeons, residents and fellows in neurology or neurosurgery, epileptologists and allied healthcare workers in epilepsy.

14:00	Introduction	
14:10	Adult intractable epilepsy: Clinical overview and investigations	Don Gross, (Edmonton, AB)
14:30	Discussion	
14:35	Adult intractable epilepsy: Epidemiology and economic burden	Sam Wiebe, (Calgary, AB)
14:55	Discussion	
15:00	Adult intractable epilepsy: Surgery	Andrew Parrent, (London, ON)
15:20	Discussion	
15:25	Break	
15:40	Neuroimaging in intractable epilepsy	Andrea Bernasconi, (Montreal, QC)
16:00	Discussion	
16:05	Development of a comprehensive epilepsy centre	Taufik Valiente, (Toronto, ON)
16:25	Discussion	
16:30	Pediatric intractable epilepsy: Clinical overview and investigations	Mary Connolly, (Vancouver, BC)
16:50	Discussion	
16:55	Pediatric intractable epilepsy: Surgery	James Rutka, (Toronto, ON)
17:15	Discussion and evaluation	

Neurocritical Care Course

Salon 3 - 14:00-17:30

Chairs: Draga Jichici, Jeanne Teitelbaum

Learning Objectives: At the completion of this symposium, participants will be able to:

1. Apply hypothermia treatment in selected patient groups
2. Treat effectively status epilepticus
3. Understand the mimickers of brain death
4. Assess and diagnose neuromuscular weakness in the ICU setting
5. Review new techniques in the diagnosis and management of traumatic brain injury
6. Prognosticate outcome following cardiac arrest

Target Audience: Practicing neurologists, neurosurgeons, critical care physicians, residents and nurses.

14:00	The management of status epilepticus	Martin Savard, (London, ON)
14:30	Hypothermia in Neurocritical Care: When to use it	Draga Jichici, (Hamilton, ON)
15:15	New approaches to generalized weakness in the ICU	Charles Bolton, (Kingston, ON)
15:45	Brain Death: Or is it?	Jeanne Teitelbaum, (Montreal, QC)
16:15	What's new in management of traumatic brain injury: Microdialysis	David Zygun, (Calgary, AB)
16:45	Discussion and evaluation	

Plenary Session: CNS, CACN, and CSCN Neurology

Salon 12 - 08:30-10:00

Chair: Richard Desbiens

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Discuss new developments in the management of inflammatory myopathies
 2. Understand the causes and life course of persons born with "cerebral palsy", and the broad principles of managing such patients

- 08:30 Welcome and Introduction
- 08:35 **Gloor Lecture - Inflammatory myopathies - New developments**Tony Amato, (Boston, MA, USA)
- 09:20 **Richardson Lecture - A Moving Target: Contemporary challenges in Cerebral Palsy across the lifespan**
.....Michael Shevell, (Montreal, QC)

Plenary Session: CNSS Neurosurgery

Salon 2 - 08:30-10:00

Chair: Derek Fewer

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Understand the principles of endoscopic neurosurgery
 2. Review the outcomes and complications of endoscopic neurosurgery
 3. Discuss the surgical and endovascular treatment of dural arteriovenous fistulas

- 08:30 Welcome and Introduction
- 08:35 **Penfield Lecture - Principles of Endoscopic Neurosurgery: Outcomes and Complications over a Decade and 700 Patients** .
.....Amin Kassam, (Pittsburgh, PA, USA)
- 09:20 **Surgical and endovascular management of cranial and spinal dural arteriovenous fistulas**Charles Haw, (Vancouver BC)

Platform Sessions (6 concurrent)

Salon 2,3,4,5,6 & 12, 13,14 - 10:15-12:30

Lunch / Digital Poster and Exhibit Viewing

Salon 8,9,10,11 - 12:30-14:00

Platform Sessions (7 concurrent)

Salon 2,3,4,5,6 & 12,13,14,15,16 - 14:00-16:30

Digital Poster and Exhibit Viewing

Salon 8,9,10,11 - 16:30-18:00

Distinguished Guest Lecturer

Salon 12 - 08:30-09:30

Plenary generously supported through an unrestricted educational grant from the Canadian Journal of Neurological Sciences.

Learning Objectives: At the completion of this symposium, participants will be able to:

1. Review the history of the development of neurosurgery and neurology
2. Discuss the burden of neurological disease, disorders and injuries in Canada

08:30 Welcome and Introduction

08:40 **From Osler to Cushing - The Rise of Medicine, the Rise of Neurosurgery**.....Michael Bliss, (Toronto, ON)

The CBANHC Report

Salon 12 - 09:30-09:50

09:30 **The Burden of Neurological Diseases, Disorders and Injuries in Canada**.....
..... Charles Tator, (Toronto, ON); Garth Bray, (Montreal, QC)

CJNS Reviewer of the Year Award Presentation & Introduction of the new CJNS Editor

Salon 12 - 09:50-10:00

Digital Poster and Exhibit Viewing

Salon 8,9,10,11 - 10:00-10:15

Grand Rounds

Salon 12 - 10:15-12:00

Chairs: Richard Camicioli, Michael Hill

Learning Objectives: At the completion of this symposium, participants will be able to:

Utilize the grand rounds format to have an interactive multidisciplinary case discussion

Neurology Case:Taim Muayqil, (Zaeem Siddiqui, Richard Camicioli)

Depression and mild cognitive impairment

Neurosurgery Case:Fred Lam, (Matt Wheatley, Wendy Johnston, Ted Roberts)

Motor neuron disease and the neurosurgeon

Pediatric Neurology Case:Vijay Ramaswamy, (Lawrence Richer, Hanna Kolski)

Bilateral cysts and spontaneous subdural hemorrhage

Lunch / Digital Poster and Exhibit Viewing

Salon 8,9,10,11 - 12:00-13:30

Headache Course**Salon 2 - 13:30-17:00***Course generously supported through an unrestricted educational grant from Procter & Gamble.***Chair:** Marek Gawel

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Assess contributory factors and etiology in patients with chronic headache
 2. Integrate knowledge of pathophysiology and pharmacological causes of chronic headache
 3. Establish a multidisciplinary treatment plan
 4. Select appropriate pharmacological and non pharmacological therapies in chronic headache

Target Audience: General neurologists

13:30	Welcome	Marek Gawel, (Toronto, ON)
13:45	Recent advances in pathophysiology including recent PET data	Michael Aubé, (Montreal, QC)
14:00	Patent foramen vale and CNS white matter lesions in migraine: Current concepts	Werner Becker, (Calgary, AB)
14:15	Chronic tension type headache	Michael Aubé, (Montreal, QC)
14:45	Transformed Migraine	Lara Cooke, (Calgary, AB)
15:15	Tension type headache in children	Shashi Seshia, (Saskatoon, SK)
15:30	Post traumatic headache	Marek Gawel, (Toronto, ON)
16:00	Chronic Cluster and trigeminal autonomic cephalalgias	Suzanne Christie, (Ottawa, ON)
16:30	Discussion and evaluation	

What's New in Neurosurgery Course**Drawing Room Fairmont - 13:30-17:00****Chair:** Rick Moulton

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Review management options and outcomes of patients with hydrocephalus
 2. Identify emerging therapies and management options for AVMs.
 3. Articulate novel treatment options and related outcomes in severe brain injury
 4. Discuss emerging therapies and management options in the patient with glioma
 5. Select appropriate management strategies for spinal metastasis
 6. Compare outcomes and treatment options for temporal lobe epilepsy

Target Audience: Neurosurgeons, neurosurgical residents, neurologists

13:30	Hydrocephalus	Ab Kulkarni, (Toronto, ON)
14:00	AVMs	Ian Fleetwood, (Halifax, NS)
14:30	Severe Brain Injury	Rick Moulton, (Ottawa, ON)
15:00	Gliomas	Ian Parney, (Calgary, AB)
15:30	Spinal Metastasis	Daryl Fourney, (Saskatoon, SK)
16:00	Temporal lobe epilepsy	Matt Wheatley, (Edmonton, AB)
16:30	Discussion and evaluation	

EEG Course

Salon 4 - 13:30-17:00

Chair: Seyed Mirsattari

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Recognize commonly encountered normal and abnormal EEG patterns in patients with epilepsy
 2. Review the characteristics of EEG in the neonate and pediatric population
 3. Appreciate the fundamentals of EEG technology including digital technology

Target Audience: Neurologists, neurology residents and pediatric neurologists.

13:30	Neonatal EEG - Normal and abnormal	Eli M. Mizrahi, (Houston, TX, USA)
14:15	Discussion	
14:20	Pediatric EEG	Warren T. Blume, (London, ON)
15:05	Discussion	
15:10	Break	
15:15	Adult EEG - Normal and patients with epilepsy	Richard S. McLachlan, (London, ON)
16:00	Discussion	
16:05	Fundamentals of EEG technology, with an emphasis on digital techniques	Susan Rahey, (Halifax, NS)
16:50	Discussion and evaluation	

Dementia Course

Salon 3 - 13:30-17:00

Course generously supported through an unrestricted educational grant from Pfizer Inc.

Chair: Gabriel Léger

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Recognize the common presentations on non- Alzheimer's dementias (mixed/vascular, Lewy body/Parkinson's disease, and frontotemporal) and how they differ from the typical Alzheimer's disease (AD)
 2. Utilize sensitive bedside cognitive testing to help differentiate these dementias from AD
 3. Diagnose these dementias based on current consensus diagnostic criteria
 4. Determine a treatment plan tailored to the non-Alzheimer's dementia, including which drugs to use and which to avoid

Target Audience: Neurologists

13:30	From vascular dementia to vascular cognitive impairment	Christian Bocti, (Montreal, QC)
14:15	Discussion	
14:45	Parkinson's disease dementia and Lewy body disease	Céline Chayer, (Montreal, QC)
15:30	Discussion	
15:45	Diagnosis and management of the frontotemporal dementias	Gabriel Léger, (Montreal, QC)
16:30	Discussion and evaluation	

MS Course

Salon 5/6 - 13:30-17:00

Chair: Kenneth Warren

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Understand the magnitude and character of MS in Canadian society
 2. Discuss the qualitative and quantitative changes in cerebrospinal fluid and neuropathological features of MS
 3. Review new developments in pathology and pharmacology affecting the management of MS

Target Audience: General neurologists and neurologists who specialize in MS.

13:30	MRI developments	Derrick Emery, (Edmonton, AB)
13:45	Discussion	
13:50	Changing demographic and clinical trends	Sharon Warren, (Edmonton, AB)
14:05	Discussion	
14:10	Quality of life	Karen Turpin, (Edmonton, AB)
14:25	Discussion	
14:30	Neuropathological variability	Lothar Resch, (Edmonton, AB)
14:45	Discussion	
14:50	Break	
15:10	Neuron loss and neuroprotection	Fabrizio Giuliani, (Edmonton, AB)
15:25	Discussion	
15:30	New therapeutic developments	Greg Blevins, (Edmonton, AB)
15:45	Discussion	
15:50	Neurovirology	Chris Power, (Edmonton, AB)
16:05	Discussion	
16:10	Experiences of institutionalized patients	Garry Wheeler, (Edmonton, AB)
16:25	Discussion	
16:30	CSF antibodies	Ingrid Catz, (Edmonton, AB)
16:45	Discussion and evaluation	

What's New in Neurology?

Wedgewood Fairmont - 13:30-17:00

Chair: Ashfaq Shuaib

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Discuss new treatment options and management of ALS
 2. Review advances in the treatment of infections of the CNS
 3. Outline the treatment options and new therapies for CNS tumours
 4. Articulate advances in neuromuscular disease
 5. Describe existing and novel treatment options for intracranial hemorrhage

Target Audience: Neurologists, neurology residents, nurses, fellows and neurosurgeons.

13:30	Introduction	
13:40	What's new in neuromuscular?	Douglas Zochodne, (Calgary, AB)
14:15	Discussion	
14:20	What's new in infections?	Chris Power, (Edmonton, AB)
14:55	Discussion	
15:00	What's new in intracranial hemorrhage?	Ashfaq Shuaib, (Edmonton, AB)
15:35	Discussion	
15:40	What's new in ALS?	Mike Strong, (London, ON)
16:15	Discussion	
16:20	What's new in CNS tumours?	Ian Parney (Calgary, AB)
16:55	Discussion and evaluation	

Neuromuscular Course

Salon 12 - 13:30-17:00

Chair: Mike Nicolle

- Learning Objectives:** At the completion of this symposium, participants will be able to:
1. Differentiate and manage common and uncommon entrapment neuropathies
 2. Diagnosis disorders affecting the brachial and lumbosacral plexus
 3. Explain the relationship between the basic physiology of nerve function and peripheral nerve pathology in diabetes
 4. Articulate the clinical manifestations of diabetic neuropathies
 5. Integrate knowledge of genetic mechanisms of congenital myotonic dystrophy with the clinical manifestations and diagnostics tests available

Target Audience: Allied health care workers, neurology and physiatry residents and fellows; academic and community neurologists and physiatrists with an interest or learning need in the field of neuromuscular neurology and physiatry.

13:30	Focal peripheral neuropathies: Focus on specific diagnostic and management challengesJohn Stewart, (Vancouver, BC)
14:00	Discussion
14:15	Brachial and lumbosacral plexopathies: Clinical dilemmas and atypical variantsKristine Chapman, (Vancouver, BC)
14:45	Discussion
15:00	Break
15:30	Congenital Myotonic Dystrophy: A review and update from the Canadian Surveillance and Cohort StudyCraig Campbell, (London, ON)
16:00	Discussion
16:15	Diabetic neuropathy: New directionsDouglas Zochodne, (Calgary, AB)
16:45	Discussion and evaluation

WINNERS OF THE 2007 SOCIETY PRIZES

THE PRESIDENT'S PRIZE – CANADIAN ASSOCIATION OF CHILD NEUROLOGY

Novel corticospinal tract pre-wallerian degeneration in pediatric stroke: acute MRI prediction of outcome and TMS correlates of reorganization

A Kirton (Toronto), T Domi (Toronto), R Chen (Toronto), M Shroff (Toronto),
C Gunraj (Toronto), E Kouzmatcheva (Toronto), G deVeber (Toronto)*

FRANCES McNAUGHTON MEMORIAL PRIZE – CANADIAN NEUROLOGICAL SOCIETY

Dominantly inherited essential cortical myoclonus in a large Canadian Mennonite family

JL Steckley (London), G Gibson (Vancouver), A Kirk (Saskatoon), AF Hahn (London)*

ANDRE BARBEAU MEMORIAL PRIZE - CANADIAN NEUROLOGICAL SOCIETY

The role of microglia in ALS

L Korngut (London), L Ang (London), M Strong (London)*

HERBERT JASPER PRIZE – CANADIAN SOCIETY OF CLINICAL NEUROPHYSIOLOGISTS

Failure of corticosteroid iontophoresis to treat carpal tunnel syndrome: a double-blind randomized controlled trial

N Amirjani (Winnipeg), SG Rennie (Edmonton), NL Ashworth (Edmonton), J Watt (Edmonton), T Gordon (Edmonton), K Chan (Edmonton)*

K.G. McKENZIE PRIZE IN CLINICAL NEUROSCIENCE RESEARCH - CANADIAN NEUROSURGICAL SOCIETY

**The impact of therapeutic modality on outcomes following repair of ruptured intracranial aneurysms:
An administrative data analysis**

CJ O'Kelly (Toronto), A Kulkarni (Toronto), P Austin (Toronto), D Urbach (Toronto), M Wallace (Toronto)*

K.G. McKENZIE PRIZE IN BASIC NEUROSCIENCE RESEARCH - CANADIAN NEUROSURGICAL SOCIETY

Enhancement of sensorimotor behavioural recovery in parkinsonian rats with a multitarget basal ganglia dopaminergic and GABAergic transplantation strategy

K Mukhida (Halifax), M Hong (Halifax), M McLeod (Halifax), G Miles (Halifax), N Kobayashi (Halifax),
B Baghbaderani (Calgary), A Sen (Calgary), L Behie (Calgary), R Brownstone (Halifax), I Mendez (Halifax)*

CHAIR'S SELECT PLENARY PRESENTATIONS

CHAIRS: JOHN STEWART, MIKE TYMIANSKI

SALON 12

- A-01 Prospective error recording in surgery: an analysis of 1108 elective neurosurgical cases**
SS Stone (Toronto), M Bernstein (Toronto)*
- A-02 Epilepsy surgery in children under 3 years of age: A Canadian wide survey**
P Steinbok (Vancouver), YC Gan (Vancouver), MB Connolly (Vancouver), L Carmant (Montreal), B Sinclair (Edmonton), J Rutka (Toronto), R Griebel (Saskatoon), K Aronyk (Edmonton), W Hader (Calgary), E Ventureyra (Ottawa)*
- A-03 The impact of therapeutic modality on outcomes following repair of ruptured intracranial aneurysms: An administrative data analysis.**
CJ O'Kelly (Toronto), A Kulkarni (Toronto), P Austin (Toronto), D Urbach (Toronto), M Wallace (Toronto)*
- A-04 STN-DBS for Parkinson's disease: variation in outcomes and adverse effects**
P Itthimethin (Calgary), K Doig-Beyaert (Calgary), K Hunka (Calgary), O Suchowersky (Calgary), S Kraft (Calgary), Y Starreveld (Calgary), M Kwan (Calgary), ZH Kiss (Calgary)*
- A-05 Dominantly inherited essential cortical myoclonus in a large Canadian Mennonite family**
JL Steckley (London), G Gibson (Vancouver), A Kirk (Saskatoon), AF Hahn (London)*
- A-06 Failure of corticosteroid iontophoresis to treat carpal tunnel syndrome: a double-blind randomized controlled trial**
N Amirjani (Winnipeg), SG Rennie (Edmonton), NL Ashworth (Edmonton), J Watt (Edmonton), T Gordon (Edmonton), K Chan (Edmonton)*

GENERAL NEUROSURGERY I

CHAIR: TAUFIK VALIANTE

SALON 4

- B-01 Intraoperative monitoring of cochlear nerve function**
DW Rowed (Toronto), DA Houlden (Toronto)*
- B-02 ETV (Endoscopic third ventriculostomy) does ventricular size correlate with clinical outcome?**
G Lapointe (Québec), M Lapointe (Québec), A Turmel (Québec)*
- B-03 A prospective study of awake craniotomy used routinely and non-selectively for supratentorial tumors**
D Serletis (Toronto), M Bernstein (Toronto)*
- B-04 Visual fields are preserved in acromegalic patients treated with SRT**
IG Fleetwood (Halifax), DB Clarke (Halifax), L Clarke (Halifax), S Imran (Halifax), E Ur (Halifax), DE Rheume (Halifax), LA Mulroy (Halifax)*
- B-05 Histopathological examination in routine discectomy: a cost-benefit analysis**
AS Wu (Saskatoon), DR Fourney (Saskatoon)*
- B-06 High grade glioma in Canada: are there regional differences?**
JF Megyesi (London), C DeSilva* (London)*
- B-07 Early neurosurgical intervention in the management of central nervous system blastomycosis**
G Marchuk (Winnipeg), M Del Bigio (Winnipeg), S Krawitz (Winnipeg), J Embil (Winnipeg), P McDonald (Winnipeg)*
- B-08 The role of recombinant activated factor VII in neurosurgery: hope or hype?**
GW Hawryluk (Toronto), MD Cusimano (Toronto)*

GENERAL NEUROLOGY I

CHAIR: PETER BAILEY

SALON 12

- C-01 White matter high signal changes in Parkinson's disease: risk factors and correlates**
R Camicioli (Edmonton), WW Martin (Edmonton), T Bouchard (Edmonton), T Green (Edmonton), C Hanstock (Edmonton), N Fisher (Edmonton), D Emery (Edmonton)*
- C-02 Magnetic resonance imaging of progressive multifocal leukoencephalopathy in HIV positive patients**
T Nguyen (Ottawa), F Al Azri (Ottawa), C Lum (Ottawa), W Miller (Ottawa), M Kingstone (Ottawa), J Wolfe (Ottawa), G Jensen (Ottawa)*

- C-03** **Neuropathic pain is common, disabling, and greatly impairs quality of life and earning potential in Albertans: a population-based survey**
C Toth (Calgary), J Lander (Edmonton)*
- C-04** **Occipital condyle syndrome as the first presentation of disseminated malignancy: two cases and a review of the literature**
JJ Moeller (Halifax), S Shivakumar (Halifax), M Davis (Halifax), CE Maxner (Halifax)*
- C-05** **Facial nerve pathology associated with cluster headache**
DW Rowed (Toronto), JG Edmeads (Toronto)*
- C-07** **Neurology in the developing world: developing a Canadian perspective**
P Bailey (Saint John), M Freedman (Toronto), A Kirk (Saskatoon), M Beaulieu (Ottawa), R Desbiens (Quebec), JC Martin del Campo (Toronto)*
- C-08** **Cerebral venous thrombosis in Singapore, 1994-2007**
H Chua (Singapore), J Chai (Singapore)*

GENERAL PEDIATRIC NEUROLOGY

CHAIR: ELAINE WIRRELL

SALON 5&6

- D-01** **Neonatal Arterial Ischemic Stroke in the Canadian Registry**
G deVeber (Toronto), C Group (Toronto)*
- D-02** **Novel corticospinal tract pre-wallerian degeneration in pediatric stroke: acute MRI prediction of outcome and TMS correlates of reorganization.**
A Kirtan (Toronto), T Domi (Toronto), R Chen (Toronto), M Shroff (Toronto), C Gunraj (Toronto), E Kouzmatcheva (Toronto), G deVeber (Toronto)*
- D-03** **Decompressive hemicraniectomy for malignant hemispheric infarction in children**
V Ramaswamy (Edmonton), V Mehta (Edmonton), LP Richer (Edmonton), P Massicotte (Edmonton), JY Yager (Edmonton)*
- D-04** **Neuroimaging challenges in the diagnosis of pediatric arterial ischemic stroke**
A Pontigon (Toronto), M Rafay (Winnipeg), J Chiang (Toronto), M Adams (Toronto), A Jarvis (Toronto), F Silver (Toronto), G deVeber (Toronto)*
- D-05** **Chronic daily headache (CDH) in children and adolescents: a prospective Saskatchewan study**
SS Seshia (Saskatoon), DF Phillips (Saskatoon), CL von Baeyer (Saskatoon)*
- D-06** **Head and neck infections in children with cerebral sinovenous thrombosis**
L Billingham (Edmonton), G deVeber (Toronto)*
- D-07** **Symptomatic white matter injury following methotrexate treatment in childhood**
N Makhani (Toronto), J Hukin (Vancouver)*
- D-08** **Gestational diabetes mellitus : risk of newborn brain injury**
N Lynch (Vancouver), EH Roland (Vancouver), K Poskitt (Vancouver), S Miller (Vancouver), M Sargent (Vancouver), A Hill (Vancouver)*
- D-09** **A phenomenological study on parental experience in pediatric neuromuscular disorders**
JK Mah (Calgary), D McNeil (Calgary), J Thannhauser (Calgary), H Kolski (Edmonton), D Dewey (Calgary)*

STROKE

CHAIR: GORDON GUBITZ

SALON 3

- E-01** **The Transcranial Doppler (TCD) flow finding at the site of occlusion predicts response to intravenous stroke thrombolysis**
M Saqqur (Edmonton), G Tsigoulis (Phoenix), AM Demchuk (Calgary), CM Molina (Barcelona), A Shuaib (Edmonton), Av Alexandrov (Phoenix)*
- E-02** **Magnetic resonance molecular imaging of endothelial activation in acute stroke**
AY Jin (Calgary), D Rushforth (Calgary), R Filfil (Montreal), J Kaur (Calgary), F Ni (Montreal), B Tomanek (Calgary), U Tuor (Calgary), PA Barber (Calgary)*
- E-03** **Matrix metalloproteinase-3 is neurotoxic in cell culture and in intracerebral hemorrhage in mice**
M Xue (Calgary), V Yong (Calgary)*

- E-04 Multiple interventions for neuroprotection utilizing thermal-regulation in the emergent treatment of stroke: the MINUTES study**
MM Siddiqui (Edmonton), Y Ludwig (Edmonton), Y Bhagat (Edmonton), MS Hussain (Edmonton), A Mateer (Edmonton), D Manawadu (Edmonton), M Saqqur (Edmonton), C Beaulieu (Edmonton), A Shuaib (Edmonton)*
- E-05 The Combination of Clinical features, Transcranial Doppler and ASPECTS score in predicting outcome in IV rt-PA treated patients**
S Husain (Edmonton), AV Alexandrov (Phoenix), AM Demchuk (Calgary), G Tsivgoulis (Phoenix), A Shuaib (Edmonton), M Saqqur (Edmonton)*
- E-06 Quantified T1 and T2 as useful adjuncts to DWI for early infarct detection in permanent and transient MCAO**
J Kaur (Calgary), U Tuor (Calgary), Z Zhao (Calgary), H Assem (Calgary), J Lee-Petersen (Calgary), T Foniok (Calgary), P Barber (Calgary)*
- E-07 Intracranial nonocclusive thrombus on CT angiography: reason to be concerned?**
V Puetz (Calgary), I Dzialowski (Dresden), S Subramaniam (Calgary), A Krol (Calgary), AM Demchuk (Calgary)*
- E-09 Rapid cognitive improvement in a patient with Susac Syndrome following plasma exchange: a case report**
FJ Mateen (Rochester), A Zubkov (Rochester), GW Petty (Rochester), J Fulgham (Rochester)*

MULTIPLE SCLEROSIS

CHAIR: LUANNE METZ

SALON 2

- F-01 T1 Gd-enhancing lesion number and new T2 number are reduced when minocycline is combined with glatiramer acetate**
LM Metz (Calgary), D Li (Vancouver), A Traboulsee (Vancouver), M Myles (Edmonton), P Duquette (Montreal), J Godin (Montreal), M Constantin (Montreal), VW Yong (Calgary)*
- F-02 The Geospatial Relation between ultraviolet radiation and multiple sclerosis in Newfoundland**
S Sloka (St John's), WE Pryse-Phillips (St John's), M Stefanelli (St John's)*
- F-03 Neuroprotection by minocycline occurs without the intermediary of microglia**
S Liu (Calgary), E O'Ferrall (Calgary), W Yong (Calgary)*
- F-04 1000 IU of daily vitamin D is usually too little to attain a minimally adequate 25-hydroxyvitamin D level in Multiple Sclerosis patients**
P Ahluwalia (Calgary), L Metz (Calgary), R Bell (Calgary), D Patry (Calgary), W Murphy (Calgary), D McGowan (Calgary), M Yeung (Calgary), K Busche (Calgary), R Zabad (Calgary), D Hanley (Calgary)*
- F-05 Macrophages stimulated by glatiramer acetate produce growth factors for oligodendrogenesis**
C Silva (Calgary), V Skihar (Calgary), W Yong (Calgary)*
- F-06 EMMPRIN-dependent Early Metalloproteinase Regulation in Murine Experimental Autoimmune Encephalomyelitis (EAE)**
SM Agrawal (Calgary)*
- F-07 Multiple sclerosis and brain neoplasm: a report of two cases**
PG Boulton (Halifax), R MacAulay (Halifax), S Kirby (Halifax), V Bhan (Halifax)*
- F-08 Three-year outcome of minocycline treatment in patients with Multiple Sclerosis**
Y Zhang (Calgary), VW Yong (Calgary), RB Bell (Calgary), M Yeung (Calgary), D Patry (Calgary), JR Mitchell (Calgary), LM Metz (Calgary)*

EPILEPSY AND EEG

CHAIR: SEYED MIRSATTARI

SALON 13/14

- G-01 Temporal and spatial attributes of high frequency oscillations in the pre-ictal period in humans**
H Khosravani (Calgary), N Mehrotra (Calgary), M Rigby (Calgary), W Hader (Calgary), N Pillay (Calgary), S Wiebe (Calgary), P Federico (Calgary)*
- G-02 Gamma knife treatment for symptomatic epilepsy due to vascular malformations**
F Moreau (Sherbrooke), C Deacon (Sherbrooke), K Brendan (Sherbrooke), M David (Sherbrooke)*

- G-03 Self-reported Memory after temporal lobe surgery**
SM Baz (London), R McLachlan (London), S Hayman-Abello (London), P Derry (London), A Alhousawi (London)*
- G-04 Reversible widespread leukoencephalopathic changes secondary to uncontrolled partial complex epilepsy**
V Ciura (Calgary), C Toth (Calgary), D McDougall (Calgary)*
- G-05 Reorganization of semantic noun processing in left temporal lobe epilepsy**
J Edwards (Calgary), A Bass (Calgary), B Goodyear (Calgary), P Federico (Calgary)*
- G-06 Modulation of fusiform face response by emotional facial expression**
AO Hebb (Seattle), KJ Miller (Seattle), H Panagiotides (Seattle), JG Ojemann (Seattle)*
- G-07 T2 relaxometry and voxel-based statistics for MR imaging of epilepsy**
RK Kosior (Calgary), ML Lauzon (Calgary), R Frayne (Calgary), P Federico (Calgary)*
- G-08 Prevalence of non-convulsive status epilepticus in patients with impaired level of consciousness**
RA ALROUGHANI (Vancouver), M JAVIDAN (Vancouver), N AL-OTAIBI (Vancouver), A Qasem (Vancouver), H Chou (Vancouver)*
- G-09 Anticonvulsant effects on functional MRI signal characteristics**
G Mijne (Calgary), R Samji (Calgary), D Pittman (Calgary), E Jensen (Calgary), J Edwards (Calgary), B Goodyear (Calgary), P Federico (Calgary)*

GENERAL NEUROSURGERY II

CHAIR: RAMESH SAHJPAUL

SALON 4

- H-02 Comparison of section of filum terminale and non- neurosurgical management for urinary incontinence in patients with normal conus position.**
P Steinbok (Vancouver), R Kariyattil (Vancouver), A MacNeily (Vancouver)*
- H-03 Identification of the source of phosphatidylcholine for axon outgrowth and branching**
JM Carter (Edmonton), RB Campenot (Edmonton), JE Vance (Edmonton), DE Vance (Edmonton)*
- H-04 Supraorbital keyhole approach via eyebrow incision for skull base lesions**
S Stoika (Montreal), MW Bojanowski (Montreal)*
- H-06 Enhancement of sensorimotor behavioural recovery in parkinsonian rats with a multitarget basal ganglia dopaminergic and GABAergic transplantation strategy**
K Mukhida (Halifax), M Hong (Halifax), M McLeod (Halifax), G Miles (Halifax), N Kobayashi (Halifax), B Baghbaderani (Calgary), A Sen (Calgary), L Behie (Calgary), R Brownstone (Halifax), I Mendez (Halifax)*
- H-07 Motor cortex stimulation for neuropathic pain: the British Columbia experience**
H Low (Vancouver), CR Honey (Vancouver)*
- H-08 Adjunctive use of a non-ionic surfactant improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease**
M Quinn (Halifax), K Mukhida (Halifax), D Sadi (Halifax), M Hong (Halifax), I Mendez (Halifax)*
- H-09 Neurosurgery patients' knowledge and feelings about the role of residents in their care: A qualitative case study**
E Knifed (Toronto), J July (Toronto), M Bernstein (Toronto)*

NEUROMUSCULAR

CHAIR: KRISTINE CHAPMAN

SALON 5&6

- I-01 The role of microglia in ALS**
L Korngut (London), L Ang (London), M Strong (London)*
- I-02 Adverse effects of intravenous immunoglobulin therapy in patients with neuromuscular diseases are limited and tolerable**
J Nadeau (Calgary), A Bhishatbhan (Calgary), D McDougall (Calgary), C Toth (Calgary)*
- I-03 Adverse effects of acute and chronic corticosteroid therapy in patients with neuromuscular diseases are common and require greater prophylaxis**
D McDougall (Calgary), A Bhishatbhan (Calgary), J Nadeau (Calgary), C Toth (Calgary)*
- I-04 Examination of congenital DM1 from the US National Registry for Myotonic Dystrophy**
P Prendergast (London), S Magalhaes (London), C Campbell (London)*
- I-05 A unique GJB1 gene mutation in X-linked hereditary motor sensory neuropathy**
L Billingham (Edmonton), H Kolski (Edmonton)*
- I-06 National manpower survey on clinical neurophysiology laboratories in Canada**
K Chan (Edmonton), S Warren (Edmonton), G Young (London)*
- I-07 Dyspnea and the use of non-invasive positive pressure ventilation in ALS**
DC Todd (Hamilton), T Lad (Hamilton), DW Cockcroft (Saskatoon)*

PEDIATRIC EPILEPSY

CHAIR: LIONEL CARMANT

SALON 13/14

- J-01 Selective Amygdalohippocampectomy in children versus adults: experience at the University of Alberta**
A Datta (Edmonton), D Sinclair (Edmonton), M Wheatley (Edmonton), D Gross (Edmonton), S Ahmed (Edmonton)*
- J-02 Is fever associated with both a family history and occurrence of febrile seizures?**
KE Gordon (Halifax), JM Dooley (Halifax), EP Wood (Halifax), PP Bethune (Charlottetown)*
- J-03 Somatic comorbidity in children with epilepsy: a Canadian population health survey**
JF Tellez-Zenteno (Calgary), A Soofi (Calgary), L Hamiwka (Calgary), S Wiebe (Calgary), E Wirrell (Calgary)*
- J-04 Frontal lobe epilepsy surgery in childhood: outcome and critical analysis of reasons for lack of success**
MB Connolly (Vancouver), L Langill (Vancouver), P Steinbok (Vancouver)*
- J-05 Iron Deficiency and Febrile Seizures in Children**
JY Yager (Edmonton), J Tan (Edmonton), R Rosychuk (Edmonton), D Spady (Edmonton), W Craig (Edmonton), DS Hartfield (Edmonton)*
- J-06 Clinical and EEG features of cingulate epilepsy in children**
DV Schrader (Vancouver), L Langille (Vancouver), A Singhal (Vancouver), P Steinbok (Vancouver), M Connolly (Vancouver)*
- J-07 Physical activity in children/teens with epilepsy compared with that in their siblings without epilepsy**
JS Wong (Edmonton), E Wirrell (Calgary)*
- J-08 Outcome after Vagal Nerve Stimulation in Children with Intractable Epilepsy**
P Steinbok (Vancouver), MB Connolly (Vancouver), EM Sherman (Calgary), K Farrell (Vancouver)*

CEREBROVASCULAR SURGERY AND INTERVENTIONAL APPROACHES

CHAIR: IAN FLEETWOOD

SALON 12

- K-01 Proposal for development of a Canadian Intracranial Aneurysm (CIA) Registry**
L DaCosta (Toronto), J Spears (Toronto), B Gray (Toronto), R Macdonald (Toronto), T Marotta (Toronto), W Montanera (Toronto), M Tymianski (Toronto), M Wallace (Toronto)*
- K-02 Cerebrovascular reactivity changes predict neurological outcome after surgical revascularization for supraclinoid obliterative vasculopathy**
T Kretschmer (Toronto), DJ Mikulis (Toronto), P Dirks (Toronto), L daCosta (Toronto), M Tymianski (Toronto)*

- K-03 Multimodality treatment of posterior fossa arteriovenous malformations**
ME Kelly (Cleveland), S John (Ottawa), R Guzman (Stanford), TE Bell-Stephens (Stanford), R Bower (Stanford), S Hamilton (Stanford), MP Marks (Stanford), HM Do (Stanford), GK Steinberg (Stanford)*
- K-04 Expediting carotid endarterectomy via a rapid access neurovascular clinic**
C Harraher (Halifax), C Dawson (Halifax), I Fleetwood (Halifax), G Gubitz (Halifax), S Phillips (Halifax), G Mackean (Halifax)*
- K-05 Wait times for carotid endarterectomy for symptomatic patients in community practice**
ML Setiawan (Calgary), MD Hill (Calgary), JH Wong (Calgary)*
- K-06 Revascularization surgery in moyamoya disease improves clinical disability and reduces the incidence of new TIA or stroke**
R Guzman (Stanford), ME Kelly (Cleveland), T Bell-Stephens (Stanford), GK Steinberg (Stanford)*
- K-07 Dynamic imaging of a model of saccular intracranial aneurysms using ultra-high resolution flat-panel volume CT**
AP Mitha (Boston), B Reichardt (Boston), CS Ogilvy (Boston), R Gupta (Boston)*
- K-08 Unruptured cerebral aneurysms presenting with ischemic events**
N McLaughlin (Montreal), MW Bojanowski (Montreal)*
- K-09 Simvastatin causes endothelin-1-mediated vascular smooth muscle cell relaxation in a cellular-engineered model of cerebral vasospasm**
AP Mitha (Cambridge), ER Balesh (Cambridge), RE Horton (Cambridge), ML McCain (Cambridge), ML O'Grady (Cambridge), KK Parker (Cambridge)*

SPINE

CHAIR: ERIC MASSICOTTE

SALON 2

- L-01 Is age a key determinant of neurological outcome following traumatic spinal cord injury? Analysis of the Second National Acute Spinal Cord Injury Study (NASCIS 2) database**
JC Furlan (Toronto), MG Fehlings (Toronto), MB Bracken (New Haven)*
- L-02 Motoneuron cell death is not responsible for the impaired nerve regeneration after chronic and sequential nerve injury**
R Midha (Calgary), Q Xu (Calgary), J Forden (Calgary), T Gordon (Edmonton)*
- L-03 Transient SSEP change can detect iatrogenic spinal cord injury during spine surgery**
DA Houlden (Toronto), M Nolan (Toronto), DW Rowed (Toronto), ML Schwartz (Toronto), M Fazl (Toronto), F Pirouzmand (Toronto), JA Finkelstein (Toronto), A Yee (Toronto)*
- L-04 Autologous activated macrophage implantation in a large animal model of spinal cord injury: motor recovery without axonal regeneration**
R Assina (Phoenix), C Ma (Phoenix), T Sankar (Phoenix), KM Horn (Phoenix), N Theodore (Phoenix), AR Gibson (Phoenix), MC Preul (Phoenix)*
- L-05 Reorganization of the primary motor and sensory cortices in patients with spinal cord compression: a pre and post-surgical evaluation using functional MRI**
D Rabin (London), RL Barry (London), R Bartha (London), JS Gati (London), M Fink* (London), N Duggal (London)*
- L-06 A prospective study to assess the reliability of a digital imaging-based assessment for cord compression and canal compromise after traumatic cervical spinal cord injury**
JC Furlan (Toronto), MG Fehlings (Toronto), EM Massicotte (Toronto), B Aarabi (Baltimore), A Vaccaro (Philadelphia), CM Bono (Boston), I Madrazo (Mexico City), C Villanueva (Barcelona), J Grauer (New Haven), D Mikulis (Toronto)*
- L-07 Kyphoplasty - expanding indications**
R Sahjpaul (Vancouver), S Gul (North Vancouver), J Padilla (North Vancouver), J Clement (Vancouver)*
- L-08 Posterolateral or transverse lumbar interbody fusion (PLIF or TLIF) procedure for degenerative lumbosacral disease via a minimally invasive approach: a retrospective comparative study**
N Marcotte (Quebec City), M Lacroix* (Quebec City)*
- L-09 Fusion protein of soluble TNF receptor II and a thermally responsive peptide for sustained drug delivery**
MF Shamji (Ottawa), AH Friedman (Durham), WJ Richardson (Durham), A Chilkoti (Durham), LA Setton (Durham)*

NEURO-ONCOLOGY

CHAIR: IAN PARNEY

SALON 3

- M-01 Purely endoscopic transthyroidal transphenoidal surgical approach for non-secreting macro-adenomas with suprasellar extension**
N McLaughlin (Montreal), F Lavigne (Montreal), C Beaugard (Montreal), MW Bojanowski (Montreal)*
- M-02 Practice audit: prophylactic peri-operative antiepileptic drug administration in patients with newly diagnosed malignant gliomas**
SH Lwu (Calgary), PA Forsyth (Calgary), JG Cairncross (Calgary), IF Parney (Calgary)*
- M-03 A combined epigenetic and genetic genome-wide screen identifies SPINT2 as a novel tumour suppressor gene in medulloblastoma**
PN Kongkham (Toronto), P Northcott (Toronto), Y Nakahara (Toronto), MD Taylor (Toronto), JT Rutka (Toronto)*
- M-04 Immunotherapy with a synthetic peptide improves response to radiotherapy in a murine glioma model**
T Sankar (Phoenix), R Assina (Phoenix), C Ma (Phoenix), LL Eggink (Tempe), J Hooper (Tempe), SW Coons (Phoenix), AC Scheck (Phoenix), MC Preul (Phoenix)*
- M-05 Complications associated with frame-based stereotactic diagnostic brain biopsy: a 622 case single-surgeon series**
PN Kongkham (Toronto), E Knifed (Toronto), M Bernstein (Toronto)*
- M-06 Identification of a mutation of the transmembrane/cytoplasmic domain of the cation independent mannose 6-phosphate receptor (CI-M6PR) in gliomas. An evaluation of receptor expression and function**
RG Kerr (Edmonton), B Motyka (Edmonton), M Farr-Jones (Edmonton), H Chen (Edmonton), CR Bleackley (Edmonton), KC Petruk (Edmonton)*
- M-07 Screening for CNS tumour therapy sensitivity using an ex vivo invasion assay**
E Dyer (London), P Costello (London), W McDonald (London), D MacDonald (London), R Hammond (London), Y Caumartin (London), R Hernandez (London), J Megyesi (London)*
- M-08 Normal human monocytes cultured with glioma cells resemble myeloid suppressor cells**
IF Parney (Calgary), JC Rodrigues (Calgary), G Gonzalez (Calgary), L Zhang (Calgary), G Ibrahim (Calgary), JJ Kelly (Calgary), PA Forsyth (Calgary), VW Yong (Calgary)*
- M-09 Purely endoscopic transthyroidal transphenoidal approach for Cushing's disease**
MW Bojanowski (Montreal), N McLaughlin (Montreal), C Beaugard (Montreal), F Lavigne (Montreal)*
- M-10 Recurrent low grade gliomas: prognosis and volumetric analysis of resection**
AO Hebb (Seattle), DL Silbergeld (Seattle), RC Rostomily (Seattle)*

CRITICAL CARE

CHAIR: JEANNE TEITELBAUM

SALON 15/16

- N-01 EEG for Prognosis after cardiac arrest**
EA AL Thenayan (London), M Savard (Quebec), M Sharpe (London), L Norton (Ste-Catharines), GB Young (London)*
- N-02 Functional MRI and EEG in the comatose survivor of cardiac arrest**
TE Gofton (London), GB Young (London), F Bihari (London), A Dencev (London), M Nicolle (London), DH Lee (London), MD Sharpe (London), SM Mirsattari (London)*
- N-03 Effect of hyperthermia on outcome in patients with aneurysmal subarachnoid hemorrhage**
BW Lo (Mississauga), D Jichici (Hamilton), L Thabane (Hamilton), L Gould (Hamilton), E Klourfeld (Hamilton)*
- N-04 Factors influencing neurologic outcome in aneurysmal subarachnoid hemorrhage patients**
BW Lo (Hamilton), D Jichici (Hamilton), L Thabane (Hamilton)*
- N-05 The frequency and clinical impact of hyperglycemia after acute spinal cord injury: a controlled cohort study with molecular examination of human spinal cord tissue**
JC Furlan (Toronto), MG Fehlings (Toronto)*
- N-06 Continuous EEG-monitoring for sedation management in severe GBS - a report of two cases**
M Savard (Quebec), EA AL Thenayan (London), MD Sharpe (London), L Norton (Ste-Catharines), GB Young (London)*

PLATFORM / POSTER PRESENTATIONS

- N-07** **Detection of seizures in ICU by a 4-channel bedside system compared to standard EEG**
M Savard (Quebec), EA AL Thenayan (London), MD Sharpe (London), L Norton (Ste-Catharines), GB Young (London)*
- N-08** **The validity of predictors of poor neurological outcome following therapeutic hypothermia for cardiac arrest**
EA AL Thenayan (London), M Savard (Quebec), L Norton (Ste-Catharines), M Sharpe (London), GB Young (London)*

POSTER PRESENTATIONS

ALL POSTER PRESENTATIONS ARE LOCATED IN THE EXHIBIT HALL
(SEE DAILY EVENTS CALENDAR FOR TIMES)

CEREBROVASCULAR SURGERY AND INTERVENTIONAL APPROACHES

- P-001** **The effects of stenting and endothelial denudation on aneurysm and branch occlusion in experimental aneurysm models**
TE Darsaut (Edmonton), I Salazkin (Montreal), S Lerouge (Montreal), G Soulez (Montreal), G Gevry (Montreal), F Bouzeghrane (Montreal), J Raymond (Montreal)*
- P-002** **Monitoring of intracranial aneurysms treated with "Neuroform" stent-assisted coiling using contrast-enhanced MR angiography**
F al-Azri (Ottawa), M Santos (Ottawa), H Lesiuk (Ottawa), W Miller (Ottawa), M Goyal (Calgary), C Lum (Ottawa)*
- P-003** **Symptomatic superficial siderosis associated with an intracranial arteriovenous malformation**
N McLaughlin (Montreal), MW Bojanowski (Montreal)*
- P-004** **Ruptured cerebral aneurysm revealed by the presence of severe vasospasm**
N McLaughlin (Montreal), MW Bojanowski (Montreal)*
- P-005** **Atherosclerotic occlusive disease influences prognosis of patients with aneurysmal subarachnoid hemorrhage**
N McLaughlin (Montreal), MW Bojanowski (Montreal)*
- P-006** **Proximal anterior cerebral artery occlusion for the treatment of large and giant fusiform aneurysms: is bypass required?**
M Labib (London), D Steven (London), SJ Peerless (Florida), CG Drake (London), S Lownie (London)*
- P-007** **Stent reconstruction of wide necked aneurysms across the circle of Willis**
ME Kelly (Cleveland), R Turner, IV (Cleveland), V Gonugunta (Cleveland), HH Woo (Cleveland), PA Rasmussen (Cleveland), TJ Masaryk (Cleveland), D Fiorella (Cleveland)*
- P-008** **Assessment of brain aneurysms after endovascular coiling using high-resolution magnetic resonance angiography**
JH Wong (Calgary), AP Mitha (Calgary), M Willson (Calgary), ME Hudon (Calgary), R Sevick (Calgary), R Frayne (Calgary)*
- P-009** **Hydrocephalus after coiling of a large unruptured intracranial aneurysm**
N Chaudhary (Brampton), D Sarma (Hamilton), T Gunnarsson (Toronto), N Murty (Hamilton), P Klurfan (Hamilton)*
- P-010** **Skin necrosis after Onyx embolization of a scalp AVM**
N Chaudhary (Brampton), D Sarma (Hamilton), T Gunnarsson (Toronto), K Reddy (Hamilton), P Klurfan (Hamilton)*
- P-011** **Case cost analysis for patients undergoing surgical clipping and endovascular coiling of intracranial aneurysms at St. Michael's Hospital, University of Toronto**
L DaCosta (Toronto), J Spears (Toronto), B Gray (Toronto), T Marotta (Toronto), W Montanera (Toronto)*
- P-012** **Efficiency and security of endovascular treatment for symptomatic carotid stenosis**
D Mercier (Quebec City), G Milot (Quebec City), J Garipey (Quebec City), J Mercier (Quebec City)*

DEMENTIA

- P-013** **Do haplogroups H and U act to increase the penetrance of Alzheimer's disease?**
M Shafa Shariat Panahi (Tehran), M Houshmand (Tehran), F Fesahat (Tehran), K Gharagozli (Tehran)*
- P-014** **Efficacy of galantamine in patients with rapidly progressing Alzheimer's Disease**
F Dunbar (Toronto), S Gauthier (Montreal), F Camacho (Toronto)*
- P-015** **Two cases of sporadic Creutzfeldt Jacob disease, one with and the other without dementia at onset**
BA van Adel (Hamilton), A McDougall (Hamilton), M Puglia (Hamilton), T Xeno (Hamilton), N Nutiu (Hamilton), C Costiniuk (Hamilton), B Lo (Hamilton), R Lo (Hamilton), JP Provias (Hamilton)*

EPILEPSY AND EEG

- P-016 Somatic comorbidity in adolescents and adults with epilepsy in the general population**
A Ausaaf Soofi (Calgary), JF Tellez-Zenteno (Calgary), S Wiebe (Calgary)*
- P-017 The EEG correlates of cerebellar fits**
Y Nadeau (Quebec), R Desbiens (Quebec)*
- P-018 Simultaneous intracranial EEG-fMRI at 3 Tesla: A phantom safety study using subdural electrodes in a high-field MR environment**
SM Boucousis (Calgary), CJ Cunningham (Calgary), BG Goodyear (Calgary), P Federico (Calgary)*
- P-019 Safety and feasibility of using implanted depth electrodes for intracranial EEG-fMRI: a phantom study**
SM Boucousis (Calgary), CJ Cunningham (Calgary), BG Goodyear (Calgary), P Federico (Calgary)*

GENERAL NEUROLOGY

- P-020 Epilepsy surgery in patients above 50 years of age - preliminary meta-analysis findings**
J McDermott (St Laurent), S Wiebe (Calgary)*
- P-021 Magnetoencephalography: A systematic review of its use in localization-related epilepsy**
M Lau (London), D Yam (London), JG Burneo (London)*
- P-022 Sequential motor phenomena of secondarily generalized seizures**
SM Baz (London), WT Blume (London)*
- P-023 Metastatic testicular choriocarcinoma presenting as recurrent intracerebral haemorrhage and atypical angiographic appearance**
G Pfeffer (Vancouver), MK Heran (Vancouver)*
- P-024 Empty sella in patients with diagnosis of pseudotumor cerebri**
A Asghari Roodsari (Tehran), A Tabassi (Tehran), A Ghorbani (Tehran), H H.Kharazi (Tehran)*
- P-025 Bilateral optic nerve head hemangioma in Von Hippel Lindau Disease**
A Abdollahi (Tehran), Z Hallaji (Tehran), A Mirshahi (Tehran)*
- P-026 Ross Syndrome-a case series**
H Chua (Singapore), J Chai (Singapore), K Lim (Singapore), S Lim (Singapore)*
- P-027 Compulsive gambling induced by Pramexipole in a patient with restless leg syndrome**
B McLane (Calgary), GM Klein (Calgary)*
- P-028 Neurological complications of miliary tuberculosis**
A Kar (Lucknow)*
- P-030 Effects of vit-C on lead toxicity on rat hippocampus**
f Kermanian (Tehran)*
- P-031 Granulomatous angiitis associated with cerebral amyloid angiopathy: A case report with radio-pathological correlation**
MG Ziller (Sherbrooke), K Letourneau* (Sherbrooke), J Chenard (Sherbrooke), C Fisch (Sherbrooke), A Tsanaclis (Sherbrooke), S Gosselin (Sherbrooke)*
- P-032 Incidence of migraine in high school students in Khorramabad**
P- Bahrami (Khorramabad), S- Nadri (Khorramabad), H- Mahmmoudvand (Khorramabad)*
- P-033 Tramadol induced seizure disorder**
P- Bahrami (Khorramabad), K Mahkami (Khorramabad)*
- P-034 Longitudinal motor cortex and spinal motor neuron changes in multiple system atrophy**
T Muayqil (Edmonton), KM Chan (Edmonton), C Hanstock (Edmonton), J Wong (Edmonton), W Johnston (Edmonton), S Kalra (Edmonton)*
- P-035 Etiology of oculomotor nerve paralysis**
z Hallaji (Tehran), A Abdollahi (Tehran), A Tbsi (Tehran)*
- P-036 CADASIL**
A Malhotra (Hartford), D Chenouda (Newington)*
- P-037 Central pontine myelinolysis masquerading as a sensory neuronopathy**
JA Fraser (London), SA Morrow (London), MS Jog (London), DH Lee (London), SL Venance (London), SM Mirsattari (London)*
- P-038 Gray matter atrophy In primary lateral sclerosis**
MC Tartaglia (London), AM Rowe (London), K Findlater (London), DH Lee (London), K Kennedy (London), MJ Strong (London)*

POSTER PRESENTATIONS

- P-039 Gordon Holmes Syndrome: A case of hypogonadotropic hypogonadism and cerebellar ataxia**
FC Lam (Edmonton), MK Heran (Vancouver)*
- P-040 HIV presenting as myelopathy and bilateral optic neuropathy**
J Lee (Vancouver), G Pfeffer* (Vancouver)*
- P-041 Leukoencephalopathy with calcifications and cysts: a case report**
RK Zabad (Calgary), J Scott (Calgary), LM Metz (Calgary)*

GENERAL NEUROSURGERY

- P-042 Apoplectic resolution of a pituitary macroadenoma following cardiac surgery**
K Mukhida (Toronto), G Kolyvas (Saint John)*
- P-043 Dermal sinus tract and intradural dermoid cyst presenting in late adulthood: a case report and literature review**
A Raut (Hamilton), A Fallah* (Hamilton), K Reddy* (Hamilton)*
- P-044 Nodular Fasciitis presenting simultaneously in the obturator nerve and gracilis muscle: Case Report**
A Fallah (Hamilton), J Lu (Calgary), J Grochmal* (Calgary), L DiFrancesco (Calgary), M Khalil (Calgary), AW Clark (Calgary), R Midha (Calgary)*
- P-045 An alternative service delivery model for infants with positional plagiocephaly**
P Mortenson (Vancouver), J Rippon (Vancouver), P Steinbok (Vancouver)*
- P-046 Early versus delayed cell transplantation in the partial lesion Parkinsonian rodent model**
TJ Phillips (Halifax), D Sadi (Halifax), M Hong (Halifax), I Mendez (Halifax)*
- P-047 Chiari 1 and hydrocephalus: another treatment alternative**
G Lapointe (Québec), A Turmel (Québec)*
- P-048 The role of bFGF-2 in the retrograde repression of axonal regeneration after injury in the central nervous system**
AS Wu (Saskatoon), DR Fourney (Saskatoon), D Schreyer (Saskatoon)*
- P-049 Spontaneous regression of cervical facet synovial cysts - a case report and review of literature**
BW Lo (Hamilton), S Banglawala (Hamilton), K Reddy (Hamilton)*
- P-050 Case of Chiari Type I Malformation in an infant with Type 2 Pfeiffer Syndrome and Cloverleaf Skull Deformity: further evidence for an acquired pathogenesis**
A Al-Hayek (London), D Matic (London), A Ranger (London)*
- P-051 Decompressive hemicraniectomy in large putaminal haematoma: an Indian experience**
R Ramachandran (Trivandrum), D Anto (Tiruvalla), A T.V. (Trivandrum), S Muthuvel (Tiruvalla), R Nayar (Trivandrum)*
- P-052 Nodular Fasciitis presenting simultaneously in the obturator nerve and gracilis muscle: case report**
JK Grochmal (Calgary), A Fallah (Hamilton), J Lu (Calgary), L DiFrancesco (Calgary), AW Clark (Calgary), R Midha (Calgary)*
- P-053 Endoscopic repair of craniosynostosis**
V Mehta (Edmonton), W Beaudoin (Edmonton), L Peterson (Edmonton), K Aronyk (Edmonton)*
- P-054 Rupture of arachnoid cysts in children: a report of 2 cases**
G Murray (St. John's), FB Maroun (St. John's), J Jacob (St. John's), R Avery (St. John's), M Alam (St. John's), S Bridger (St. John's), B Cramer (St. John's)*
- P-055 Central neurocytoma: A tumour in evolution**
FB Maroun (St. John's), R Avery (St. John's), J Barron (St. John's), A Norman (St. John's), G Murray (St. John's), A Engelbrecht (St. John's), N Hache (St. John's)*
- P-056 Intracranial rhabdomyosarcoma metastasis: A case report**
G Murray (St. John's), FB Maroun (St. John's), R Avery* (St. John's), A Engelbrecht (St. John's), J Barron (St. John's)*
- P-057 Intraoperative MRI verification of extent of resection in corpus callosotomy**
P Dhaliwal (Calgary), N Pillay (Calgary), L Hamiwka (Calgary), S Wiebe (Calgary), W Hader (Calgary)*
- P-058 Ischemic white matter injury in kaolin-induced neonatal rat hydrocephalus**
OH Khan (Winnipeg), MR Del Bigio (Winnipeg)*
- P-059 Idiopathic orbital hemorrhage of extraocular muscle: case report and review of literature**
M Laroche (Montreal), N McLaughlin (Montreal), MW Bojanowski (Montreal)*

- P-060 Klippel Feil syndrome associated with a craniocervical dermoid cyst**
N McLaughlin (Montreal), J Demers (Montreal), D Shedid (Montreal)*
- P-061 Sensorimotor behaviours are not adversely affected by chronic amphetamine administration in the rat model of Parkinson's disease**
S Massoud (Halifax), D Sadi (Halifax), M Hong (Halifax), I Mendez (Halifax)*
- P-062 Angiographically-negative venous congestive myelopathy - case report**
R Sahjpaul (Vancouver), B Toyota (Vancouver)*
- P-115 Chiari-syringomyelia complex and posterior fossa decompression : relationship between radiological and clinical improvement. A consecutive series of 34 cases.**
HT Khuong (Quebec), A Turmel (Quebec)*

MOVEMENT DISORDERS

- P-063 The protective effect of quercetin in an experimental model of Parkinson disease : a behavioral and histochemical analysis in adult rat**
M Joghataei (Tehran), M Mehdizadeh (Tehran), R Aryanpour (Tehran), M Roghani (Tehran), M Nobakht (Tehran)*

MUSCULAR SCLEROSIS

- P-064 In pictures: multiple sclerosis - a neuroradiological review of its features and differential diagnoses**
S Chakraborty (Ottawa), T Nguyen (Ottawa), M Santos (Ottawa), M Kingstone (Ottawa), C Lum (Ottawa), W Miller (Ottawa)*
- P-065 Bilateral horizontal gaze palsy and severe trismus in multiple sclerosis: A case report**
S Michaud (Longueuil), L Berger (Longueuil), Z Nasreddine (Longueuil), J Boulanger (Longueuil)*
- P-066 Skin changes in patients with relapsing-remitting multiple sclerosis on immunomodulatory therapy**
RK Zabad (Calgary), D Lavorato (Calgary), DG Patry (Calgary), C Harris (Calgary), K Billesberger (Calgary), S Peters (Calgary), L Tillotson (Calgary), K Hogue (Calgary), W Wall (Calgary), LM Metz (Calgary)*
- P-068 Salivary gland radiation therapy and its effects on the functioning of patients with amyotrophic lateral sclerosis (ALS): The retrospective basis for a prospective study**
S Cleary (Edmonton), P Carey (Edmonton), N Jha (Edmonton), W Johnston (Edmonton), S Kalra (Edmonton)*

NEUROMUSCULAR

- P-069 Maximizing swallowing ability in ALS through increased sensory input: A case study**
S Cleary (Edmonton), S Krawczyk (Edmonton), S Kizar (Edmonton), S Kalra (Edmonton), W Johnston (Edmonton)*
- P-070 Juvenile seronegative generalized myasthenia gravis- an atypical presentation**
A Datta (Edmonton), H Kolski (Edmonton)*
- P-071 A supratentorial primitive neuroectodermal tumor (PNET) in an adult male**
PG Boulton (Halifax), AS Easton (Halifax), DB Clarke (Halifax)*
- P-072 Recurrent intracranial germ cell tumor with diffuse white matter and optic nerve involvement**
H Block (Edmonton), B Wheatley (Edmonton), E Johnson (Edmonton), G Blevins (Edmonton)*
- P-073 Defective dendritic cell maturation in malignant glioma patients**
IF Parney (Calgary), J Rodrigues (Calgary), L Zhang (Calgary), G Gonzalez (Calgary)*
- P-074 Gliomatosis cerebri: a case report**
L Ogieglo (Saskatoon), K Meguro (Saskatoon), S Hentschel (Saskatoon)*
- P-075 Intracranial subependymomas: clinico-pathological characteristics**
M Laroche (Montreal), F Berthelet (Montreal), MW Bojanowski (Montreal)*
- P-076 Supratentorial Extra-Axial Ependymoma: Case Report**
NR Awan (Riyadh), KN Al-Musrea (Riyadh)*

POSTER PRESENTATIONS

PEDIATRIC

- P-077 Multiple short segment laminoplasties in children: a novel technique to avoid postoperative spinal deformity**
P Steinbok (Vancouver)*
- P-078 Long-term outcome of infants with positional occipital plagiocephaly**
P Steinbok (Vancouver), D Lam (Vancouver), S Singh (Vancouver), P Mortenson (Vancouver), A Singhal (Vancouver)*
- P-079 Posterior reversible encephalopathy syndrome in the pediatric population: the Montreal Children's Hospital experience**
MG Ziller (Sherbrooke), B Rosenblatt (Montreal), C Poulin* (Montreal)*
- P-080 Acute and long term neurological complications of bacterial meningitis in children**
NJ Lowry (Saskatoon), ML Garner (Saskatoon)*
- P-081 Adherence of children to MS disease modifying therapy**
JK Mah (Calgary), LM Metz (Calgary), B Buckner (Calgary), J Bakker (Calgary), W Wall (Calgary), C Harris (Calgary)*
- P-082 Adherence in children and adolescents with recurrent headache (RH) and chronic daily headache (CDH)**
DF Phillips (Saskatoon), SS Seshia (Saskatoon), CL von Baeyer (Saskatoon), RJ Huntsman (Saskatoon)*
- P-083 Occipital bone compression of the superior sagittal sinus as a contributory factor in neonatal cerebral sinovenous thrombosis**
MA Tan (Toronto), M Shroff (Toronto), M Moharir (Toronto), A Pontigon (Toronto), G deVeber (Toronto), A Kirton (Toronto)*
- P-084 A pediatric neurology elective in the far north: a pilot experience**
A Doja (Ottawa), H McMillan (Ottawa), P Jacob (Ottawa)*
- P-085 Congenital myotonic dystrophy: An update of the Canadian incidence and cohort study**
C Campbell (London), SL Venance (London), P Jacob (Ottawa), V Siu (London)*

SPINE

- P-086 Hemilaminectomy employment in removal of spinal cord tumors**
Wm Sbeiti (Riad), A Zaki (Riad)*
- P-087 Effects of degenerative disc disease on the cervical disc height**
D Rabin (London), N Duggal (London), R Bertagnoli (Straubing), ML Fink (London),*
- P-088 Anatomical differentiation between lamina of fourth and fifth lumbar vertebrae: diagnostic and clinical perspectives in lumbar spine surgeries**
M Shimia (Tabriz), P Vahedi (Tabriz), I Lotfinia (Tabriz), A Karimpour (Tabriz)*
- P-089 Bilateral transnasal endoscopic approach to the odontoid**
BW Lo (Hamilton), A Lee (Hamilton), D Sommer (Hamilton), N Murty (Hamilton)*
- P-090 Distal spinal cord infarction simulating intramedullary tumour - a case report**
BW Lo (Hamilton), B Van Adel (Hamilton), K Reddy (Hamilton)*
- P-091 Traumatic retroclival hematoma: an uncommon pediatric injury**
K Aal Ali (Halifax), P McNeely (Halifax), W Howes (Halifax), S Walling (Halifax)*
- P-092 Unusual presentation of intramedullary post-traumatic syrinx**
G Murray (St. John's), FB Maroun (St. John's), R Avery (St. John's), A Engelbrecht (St. John's), M Stefanelli (St. John's), P Bartlett (St. John's), N Hache (St. John's), R Heale (St. John's)*
- P-093 Intracranial hypotension due to Tarlov's cyst**
G Murray (St. John's), FB Maroun (St. John's), C Go (St. John's), A Engelbrecht (St. John's), R Avery (St. John's), P Bartlett (St. John's)*
- P-094 Biomechanical evaluation of the Prestige™ cervical intervertebral disc prosthesis**
D Rabin (London), N Duggal (London), AG Brantley (Phoenix), S Baek (Phoenix), NR Crawford (Phoenix)*
- P-095 Percutaneous placement of C1-2 trans-articular screws**
M Nikolakis (Edmonton)*
- P-096 In vivo kinematic results after ProDisc-C total disc replacement**
D Rabin (London), R Bertagnoli (Straubing), N Wharton (Houston), GE Pickett (London), N Duggal* (London)*
- P-097 Grisel syndrome in adult patients. report of two cases and a review of the literature**
Y Karam (Montreal), G Boubez (Montreal), D Shedid (Montreal)*
- P-098 Case report: intramedullary neurosarcoidosis**
S Gul (North Vancouver), R Sahjpaul (Vancouver)*
- P-099 Case report: minimally invasive spinal instrumented fusion for trauma**
S Gul (North Vancouver), R Sahjpaul (Vancouver)*

STROKE

- P-100 Excellent treatment response in basilar thrombosis despite prolonged unconsciousness and brainstem radiological changes**
MS Hussain (Edmonton), T Yeo (Edmonton), MW Hussain (Edmonton), MA Hussain (Edmonton), K Butcher (Edmonton)*
- P-102 Effect of combined hypothermia and creatine on perinatal hypoxic-ischemic brain damage**
SL Hess (Edmonton), KG Todd (Edmonton), EA Armstrong (Edmonton), A Terepocki (Edmonton), JY Yager (Edmonton)*
- P-103 Unilateral critical carotid stenosis with bilateral manifestation: the shaking limbs TIA**
M Abdul (Edmonton), MM Siddiqui (Edmonton), K Khan (Edmonton), A Shuaib (Edmonton)*
- P-105 A cool handed right hemispheric stroke**
G Jickling (Edmonton), M Mouradian (Edmonton), J Scozzafava (Edmonton), A Shuaib (Edmonton)*
- P-106 How well is hyperlipidemia managed after ischemic stroke?**
D Manawadu (Edmonton), AM Nasser (Edmonton), A Mateer (Edmonton), A Shuaib (Edmonton)*
- P-107 Treatment of acute ischemic stroke affected by time-related factors**
H Hamid (Edmonton), AM Nasser (Edmonton), MS Hussain (Edmonton), M Hamadeh (Edmonton), M Siddiqui (Edmonton), A Salam (Edmonton), M Saqqur (Edmonton), A Shuaib (Edmonton), K Khan (Edmonton)*
- P-108 Emergency Medical Services (EMS) has an important role in tPA administration rate and acute stroke management**
AM Nasser (Edmonton), A Salam (Edmonton), H Hamid (Edmonton), M Hamadeh (Edmonton), M Saqqur (Edmonton), A Shuaib (Edmonton), KA Khan (Edmonton), M Siddiqui (Edmonton)*
- P-109 Caregiver burden following stroke: Identifying caregivers at risk**
H Rigby (Halifax), G Gubitz (Halifax), S Phillips (Halifax)*
- P-110 The prevalence of carotid intima media thickness in TIA or Stroke patients with and without metabolic syndrome**
P Maheshwari (Edmonton), M Ibrahim (Edmonton), S Hussain (Edmonton), C Derksen (Edmonton), M Siddiqui (Edmonton), A Mateer (Edmonton), H Haroon (Edmonton), D Manawadu (Edmonton), A Shuaib (Edmonton)*
- P-111 Stoke out come scale**
NH Rizvi (Edmonton), M Saqqur (Edmonton), A Shuaib (Edmonton)*
- P-112 Real-time dynamic assessment of cerebral hemodynamics in a patient with orthostatic aphasia: a potential application of transcranial doppler**
NH Rizvi (Edmonton), Y Alladin (Edmonton), M Saqqur (Edmonton), S Hussain (Edmonton)*

TRAUMA, CRITICAL CARE

- P-113 Management of severe traumatic brain injury in Saskatchewan**
PA Mercier (Saskatoon), J Witt (Saskatoon), K Meguro (Saskatoon)*
- P-114 Effect of troponin rise on outcome in patients with aneurismal subarachnoid hemorrhage**
BW Lo (Hamilton), D Jichici (Hamilton), L Thabane (Hamilton)*

2007 EXHIBITORS AND SPONSORS

Bayer Inc.

#1

Bayer Inc. is a Canadian subsidiary of Bayer AG, an international research-based group with core businesses in health care, crop science, and innovative materials. The Specialized Therapeutics unit of Bayer Inc. is focused on improving the lives of patients living with Multiple Sclerosis (MS) by providing innovative and effective therapies.

Biogen Idec

#20

Biogen Idec (NASDAQ: BIIB) creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For press releases and additional information about the company, please visit www.biogenidec.com.

Boehringer Ingelheim Canada Ltd.

#31

Boehringer Ingelheim Canada Ltd. (BICL) is a member of the Boehringer Ingelheim group of companies with international headquarters in Ingelheim, Germany. Boehringer Ingelheim is the largest 100% family-owned pharmaceutical company and ranks among the top 20 pharmaceutical companies in the world.

BICL has earned a well-deserved reputation for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and has expanded its product portfolio to include treatments for diseases that affect the Central Nervous System, the Cardiovascular system, and other human conditions. We invite you to visit our website www.boehringer-ingelheim.ca for more information on our company and products.

Bristol-Myers Squibb Canada

#8

Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Canada is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS), nervous system diseases and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMJ symbol.

Bristol-Myers Squibb Canada's operations are headquartered in Montréal, Québec.

Canada Microsurgical Ltd.

#12

Canada Microsurgical has been a distributor of neurosurgical products for the past 24 years. We are located in Burlington, Ontario and have representation with a DIRECT SALES FORCE throughout all of Canada.

Carl Zeiss Canada

#24

Carl Zeiss offers a complete range of visualization products, ranging from magnifying loupes to neurosurgical microscopes and accessories to meet every need and budget. We are proud to showcase the Opmi Pentero, featuring state-of-the-art optics, integrated video and digital documentation for optimum user ease and operating room workflow. Also on hand is the MediLive MindStream, a complete video documentation system geared to the demanding environment of today's busy operating room. Please visit the Carl Zeiss booth for a hands-on experience and personal consultation with one of our product experts.

Codman / Johnson & Johnson

#3

Codman markets and distributes a wide range of diagnostic and therapeutic products for the treatment of central nervous system disorders. Our focus is on Intractable Pain Management, Pediatric and Adult Hydrocephalus, and Neuro Critical Care. Our product line includes Cerebrospinal Fluid Shunts, Cerebrospinal Fluid Drainage Systems, Anti-microbial Impregnated Catheters, Advanced Neuro-Monitoring, Electrosurgical Systems, Cranial Plating, Dural Substitutes and General Instrumentation for surgical procedures.

DePuy Spine is a leading designer and manufacturer of technologies for the treatment of cervical, thoracic, lumbar and sacral pathologies.

In Canada, Codman and DePuy Spine are units of Johnson & Johnson Medical Products, a division of Johnson & Johnson Inc., and are headquartered in Markham, Ontario.

2007 EXHIBITORS AND SPONSORS

Hoffman LaRoche

#19

Roche is a leader in the research and development of pharmaceutical and diagnostic solutions that look beyond today's horizons and make a profound difference in people's lives. Working in partnership with healthcare practitioners from across the country, Roche has opened the door to countless new possibilities in the discovery, treatment and management of acute and long term disease. The company is active in a broad range of therapeutic categories including virology, oncology, transplantation and urgent care. The Urgent Care Business Unit is comprised of a dedicated team of individuals managing products for treatment of acute myocardial infarction, stroke and influenza.

latest information and related educational resources, please visit the Merck Frosst Canada booth.

Novartis Pharmaceuticals Canada Inc.

#6

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Novartis Pharmaceuticals Canada conducts hundreds of clinical trials across the country seeking new treatments including neuroscience, cardiovascular disease and cancer. The company employs approximately 800 people in Canada and its headquarters are located in Dorval, Quebec.

Janssen-Ortho Inc.

#16

Janssen-Ortho Inc. is a brand-name pharmaceutical company headquartered in Toronto with a broad range of medications used in psychiatry, neurology, dementia, attention deficit hyperactivity disorder, pain management, women's health, infectious disease, gastroenterology, and urology.

Novo Nordisk Canada Inc.

#26

"Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,000 employees in 79 countries, and markets its products in 179 countries."

Leica Microsystems

#11

Leica Microsystems is a leading global innovator, manufacturer and supplier of high precision surgical microscopes.

Medtronic of Canada Ltd.

#37

Medtronic is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

We are proud to be associated with the CNSF to highlight our products and services assisting healthcare professionals in the treatment of pain and neurological, urologic, and spinal disorders.

Pfizer Canada Inc.

#14

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world's leading pharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer Inc invests more than US\$7 billion annually in R&D in a wide range of therapeutic areas, including arthritis, cardiovascular disease, endocrinology, HIV/AIDS, infectious disease, neurological disease, oncology, ophthalmology and smoking cessation. For more information, visit www.pfizer.ca.

Merck Frosst Canada Ltd.

#22

Merck Frosst Canada Ltd. is pleased to participate in the 2007 Congress of Canadian Neurological Sciences Federation.

Merck Frosst Canada Ltd. is committed to the field of neurology with a strong focus on facilitating effective management of patients suffering from migraine. For the

2007 EXHIBITORS AND SPONSORS

Prestwick Pharmaceuticals Canada

#25

Prestwick Pharmaceuticals Canada Inc. is a late-stage product-based biopharmaceutical company engaged in the development and marketing of drugs for chronic diseases for diseases of the central nervous system (CNS). Our portfolio of drugs addresses significant unmet medical needs in CNS disorders such as Huntington's disease, Parkinson's disease, and schizophrenia.

Procter & Gamble

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands. The P&G community consists of almost 140,000 employees working in over 80 countries worldwide. P&G is the leading consumer products company in Canada with over \$2.7 billion in annual sales. Please visit www.pgcanada.ca for the latest news and in-depth information about P&G and its brands. P&G Pharmaceuticals is a division of P&G Health.

Roxon Medi-Tech Ltd.

#36

Roxon Medi-Tech Ltd. cordially invites you to visit our booth where our knowledgeable staff will present to you the latest neurology equipment - EEG, Ambulatory EEG, EMG, IOM & Sleep.

Sanofi-aventis Canada Inc.

#8

Sanofi-aventis Canada Inc. is an affiliate of the Paris-based sanofi-aventis Group, one of the world's leading pharmaceutical companies. The global company is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. With annual R&D investments of more than four billion euros, the sanofi-aventis Group is moving more than 120 products through its research pipeline in its bid to deliver products that not only improve patients' quality of life, but can also help lower the overall cost of healthcare.

In Canada, the company's core products include medications used in the treatment of hypertension, unstable angina, deep vein thrombosis, cancer, post-menopausal osteoporosis and diabetes, and in the prevention of atherothrombotic events such as heart attacks and strokes.

One of the 500 leading companies in Canada, the Canadian operation employs 1,140 people across the country and operates a state-of-the-art manufacturing facility at its corporate headquarters in Laval, Quebec.

Talecris Biotherapeutics

#18

Talecris Biotherapeutics is a new company proud to inherit a legacy of more than 60 years of providing lifesaving and life-enhancing plasma-derived therapeutic proteins. Through the assets of Bayer Biological Products' plasma business, Talecris' heritage of patient care innovations in therapeutic proteins dates back to the blood-derived products Cutter Laboratories began to produce in the early 1940s. Cutter and its successor companies, including Miles Laboratories and Bayer, were recognized in the industry as producers of innovative products, starting with the development of albumin and continuing with other products for immune deficiencies, genetic lung disease, hemophilia, and passive immunity.

Talecris, having inherited this solid foundation of unparalleled expertise and experience, is now uniquely positioned to create a new standard of excellence in the field of biotherapeutics.

The Talecris New Trials Support (Talents) Program is a novel initiative from Talecris Biotherapeutics that has been designed to support investigator-initiated trials conceived by researchers and clinicians with an interest in using intravenous immune globulin (IGIV) in areas such as immunology, hematology and neurology. Every year the Talents program will provide \$1 million to fund basic science and clinical research in these fields.

The international headquarters of Talecris Biotherapeutics are located in Research Triangle Park, North Carolina. Talecris has other offices located in Mississauga - Ontario (Canadian Headquarters), Ottawa - Ontario and Frankfurt, Germany (European Headquarters). Talecris production facilities are located in Clayton, North Carolina and at Precision Pharma Services (a wholly-owned subsidiary) located in Melville, New York.

Teva Neuroscience

#30

Teva Neuroscience is a company dedicated to improving the lives of people with neurological diseases. In our comprehensive approach to this complex illness, Teva Neuroscience created Shared Solutions®, a free patient support program that goes beyond the disease and beyond the

2007 EXHIBITORS AND SPONSORS

treatment to help people living with Multiple Sclerosis enjoy a life as full and rewarding as possible.

Teva Neuroscience's research and development efforts also encompass ALS, lupus, oncology and epilepsy. Teva Neuroscience is committed to continued innovation in the treatment of neurological and autoimmune disorders, and bringing new options to people living with these devastating diseases.

Valeant Canada Ltd / Valeant Canada limitée #13

Valeant Canada Limited is a subsidiary of Valeant Pharmaceuticals International, a global pharmaceutical company. Valeant Pharmaceuticals International's vision is to discover, develop, acquire and commercialise innovative products for the treatment of diseases with significant unmet medical needs primarily in the areas of neurology, dermatology and infectious diseases.

Valeant Canada limitée est une filiale de Valeant Pharmaceuticals International, société pharmaceutique intégrée. La vision de Valeant Pharmaceuticals International est de découvrir, mettre au point, acquérir et commercialiser des produits novateurs servant à traiter des maladies présentant d'importants besoins médicaux non satisfaits, surtout dans les domaines de la neurologie, de la dermatologie et des maladies infectieuses

XLTEK

#10

XLTEK is an established market leader in the monitoring and diagnosis of conditions affecting the central and peripheral nervous systems. We understand your needs because we listen.

XLTEK is an innovative developer and manufacturer of quality products and services for Electromyography (EMG), Electroencephalography (EEG), Long Term [Epilepsy] Monitoring (LTM), Intra-Operative Monitoring (IOM) and Polysomnography (PSG). We also offer a full portfolio of Neurodiagnostic and Sleep Accessories.

Come see what over 20 years of experience can provide to you: visit us at our booth and visit our website at www.xltek.com to see our full line of solutions. We're helping you put patient care first!

RENSEIGNEMENTS D'ORDRE GÉNÉRAL

EMPLACEMENT DU CONGRÈS ET INSCRIPTIONS

Emplacement du congrès

Shaw Conference Centre
9797 Jasper Avenue
Edmonton, Alberta T5J 1N4

Inscriptions des délégués et des exposants

Bureau des inscriptions

Shaw Conference Centre

Mardi 19 juin	07:30 – 18:30
Mercredi 20 juin	07:00 – 18:30
Jeudi 21 juin	07:00 – 18:30
Vendredi 22 juin	07:00 – 13:30

PROCHAINS CONGRES DE LA FSNC

17 – 20 juin 2008	Victoria, Colombie Britannique
9 – 12 juin 2009	Halifax, Nouvelle Ecosse
8 – 11 juin 2010	Québec, Québec

DES QUESTIONS?

Advance Group

A l'attention de la Fédération des sciences neurologiques du Canada
Suite 101 -1444 Alberni Street
Vancouver, BC, Canada V6G 2Z4
Tel: +1-604-688-9655 (Extension 2)
1-800-555-1099 (Extension 2)
Fax: +1-604-685-3521
E-mail: cnsfinfo@advance-group.com

Détails de l'inscription

Inscription complète

- Permet d'assister à toutes les séances du congrès annuel 2007 du mardi 19 juin au vendredi 22 juin.
- Inclut la réception des exposants, la réception du Président le mercredi 20 juin et le dîner du Président du jeudi 21 juin, ainsi que le repas du midi dans la salle d'exposition le jeudi et le vendredi.

Inscription pour une journée

- Ne permet d'assister qu'aux séances scientifiques du mardi, du mercredi, du jeudi et du vendredi.
- N'inclut pas la réception du Président ni le dîner du Président, mais vous pouvez acheter des billets supplémentaires pour ces événements.

Badges

- Les délégués doivent constamment porter leurs badges pour être admis aux cours du Congrès et aux séances scientifiques. Les billets seront collectés pour la réception du Président et le dîner du Président.

Formulaires d'inscription

- Vous pouvez vous inscrire en ligne à www.cnsfederation.org, ou
- Pour poster ou à envoyer par télécopie à:

Advance Group Conference Management
Suite 101 - 1444 Alberni Street
Vancouver, BC, Canada V6G 2Z4

HÉBERGEMENT

Aidez votre Fédération en réservant votre séjour à l'hôtel dans un hôtel partenaire de la FSNC et bénéficiez d'un tarif réduit! Advance Group a été désigné Bureau officiel de l'hébergement pour le 42ème Congrès de la Fédération des sciences neurologiques canadiennes qui se tiendra à Edmonton, AB du 19 au 22 juin 2007. Faites ce qu'il faut pour profiter des tarifs d'hôtel spéciaux réservés aux délégués du Congrès.

Tarifs préférentiels

La FSNC a réservé un bloc de chambres et fixé des tarifs préférentiels pour les délégués de la conférence dans les hôtels suivants:

Fairmont MacDonald

Simple ou Double	\$199
Chambre avec vue	\$219
Chambre Deluxe	\$239
Deluxe avec vue	\$259

Pour une 3ème ou 4ème personne, ajoutez \$20.00/personne/nuit au type de chambre ci-dessus.

Westin

Simple ou Double	\$165
------------------	-------

Pour une 3ème ou 4ème personne, ajoutez \$25.00/ personne/nuit au type de chambre ci-dessus.

Réservation d'hôtel

- Comment faire: Advance Group accepte les demandes d'hôtel en ligne à www.cnsfederation.org ou par télécopie au (604-685-3521) ou par la poste en utilisant un formulaire de réservation d'hôtel de la FSNC. Les réservations par téléphone ne seront pas acceptées.
 - Les demandes de renseignements sur les hôtels, les questions, ou toute demande groupée pour 10 chambres ou plus sont à envoyer à l'adresse courriel suivante: cnsf2007@advance-group.com.
 - Les réservations d'hôtel seront attribuées selon les renseignements reçus et dans l'ordre d'arrivée des demandes, selon la disponibilité des hôtels et des chambres.
 - Réservations individuelles: pour confirmer chaque réservation de chambre, un acompte de la valeur d'une nuitée est exigé, payable par carte de crédit ou par chèque/mandat à l'ordre de Advance Group. Ce chèque ou mandat (EN DOLLARS CANADIENS) doit accompagner le formulaire de réservation d'hôtel pour que votre réservation soit enregistrée. Veuillez soumettre un formulaire pour chaque chambre réservée.
 - Les confirmations d'hôtel vous seront envoyées directement par courriel, par télécopie ou par la poste.
- Tous les prix d'hôtel sont en dollars canadiens, par chambre et par nuitée. Il faut ajouter aux tarifs 4% de taxe hôtelière, 6% TPS et 1%

taxe tourisme. Les visiteurs résidant hors du Canada peuvent se faire rembourser la TPS sur la portion chambre de leur facture. Vous trouverez des formulaires de remboursement de la TPS à la caisse de l'hôtel.

EVÈNEMENTS SOCIAUX

Réception des exposants

Mercredi 20 juin 2007 - 17:30-19:00

Shaw Conference Centre - Niveau congrès-zone d'exposition

Vin et fromage. Bar payant. **Badges obligatoires pour être admis.**

Réception du Président

Mercredi 20 juin 2007 - 19:00-21:00

Empire Ballroom, Fairmont MacDonald

Tenue de ville – Rafrâichissements et hors d'oeuvres. 2 billets-boisson gratuits puis bar payant. **Les tickets d'entrée, qui font partie du forfait pour l'inscription complète, seront émis et collectés à la porte.** Des billets extra pourront s'acheter à \$30 pièce (plus taxe).

Soirée des résidents

Jeudi 21 juin 2007 - 18:00-19:00

Shaw Conference Centre - Salon 5/6

Tous les résidents sont invités à se mêler à leurs collègues et aux membres de la FSNC pour faire leur connaissance; Les boissons y seront gratuites.

Dîner du Président

Jeudi 21 juin 2007- 19:00

Shaw Conference Centre - Hall D niveau des passages pour piétons (pedway). Tenue de ville. Dîner à quatre services. Ce dîner fait partie de l'inscription complète, votre badge sera requis pour participer, les billets supplémentaires seront collectés à la porte. Des billets supplémentaires pourront s'acheter à 75\$ (plus taxe).

Lundi 18 juin 2007

09:00-16:30	FSNC/JCSN: réunions du conseil d'administration et de planification	Drawing Room Fairmont
16:30-17:30	Réunion du conseil de l'ACNP	Drawing Room Fairmont
17:00-18:00	Salle de préparation pour les conférenciers	Salon 7

Mardi 19 juin 2007

07:30-18:30	Inscription	Hall de l'étage Meeting
07:30-18:00	Salle de préparation pour les conférenciers	Salon 7
08:00-08:30	Comité de vérification JCSN	Drawing Room Fairmont
08:30-09:00	Comité de vérification FSNC	Drawing Room Fairmont
08:00-17:00	Cours de révision en neurobiologie	Salon 4
08:30-17:00	SLA, stratégies pour qualité de vie/ qualité des soins, cours symposium	Salon 3
08:30-17:00	Jour de neuropédiatrie	Salon 2
09:00-11:00	Comité de développement professionnel FSNC	Salon 19/20
10:00-12:00	Comité du programme scientifique FSNC	Salon 19/20
12:00-13:30	Déjeuner SLA	Salon 12
12:00-13:00	Réunion SCN pour les résidents de neurologie	Wedgewood Fairmont
12:00-13:00	Comité EMG, SCNC	Drawing Room Fairmont
13:00-14:00	Comité EEG, SCNC	Drawing Room Fairmont
12:30-16:30	SCN, éducation et main d'oeuvre, CR comité de spécialité neurologie	Salon 1
13:00-14:00	JCSN, conseil de rédaction	Salon 19/20
14:00-15:00	JCSN comité des publications	Salon 19/20
13:00-15:00	SLA atelier 2	Salon 15/16
13:00-15:30	SLA atelier 3	Salon 13/14
16:30-18:00	Réunion du conseil SCNC	Salon 1
16:30-18:00	Réunion du conseil SCNCH	Salon 20
16:30-18:00	Réunion du conseil SCN	Salon 19
16:30-17:30	Réunion professionnelle, résidents de neurochirurgie	Salon 17
17:00-18:00	Assemblée générale annuelle ACNP	Salon 15/16
18:00-20:00	Séance vidéo et épilepsie (cours)	Salon 4
18:00-20:00	Mouvements anormaux	Wedgewood Fairmont
18:00-20:00	SLA, groupe de pression spécialisé (GPS)	Jasper Room Fairmont
18:00-20:00	Neuromusculaire, GPS	Salon 3
18:00-20:00	Réunion pour l'enseignement aux résidents de neurochirurgie	Drawing Room Fairmont
18:00-20:00	Enseignement de neurologie aux étudiants	Salon 13 & 14
18:30	Dîner ACNP - Ruth's Chris Steak House	

Mercredi 20 juin 2007

07:00-18:30	Inscription	Hall de l'étage Meeting
07:00-18:00	Salle de préparation pour les conférenciers	Salon 7
07:00-08:00	Neurochirurgie pédiatrique	Salon 1
08:00-16:00	Installation des expositions (pour exposants)	Salons 8,9,10 & 11
08:30-10:30	S. plénière, inauguration - Progrès scientifiques et techniques dans les neurosciences cliniques	Salon 12
10:45-12:15	Présentation plénière choisie par le président	Salon 12
12:00-13:00	Mouvements anormaux, assemblée générale annuelle canadienne	Salon 1
12:00-13:00	Groupe canadien neuromusculaire	Salon 17/18
13:00-14:00	Réunion CCSCNP (Coalition canadienne pour la santé du cerveau et des nerfs périphériques)	Salon 5
14:00-17:30	Cours sur la colonne vertébrale	Wedgewood Fairmont
14:00-15:30	EMG Atelier 1	Salon 15
14:00-15:30	EMG Atelier 2	Salon 16
14:00-17:30	EMG Atelier 3	University of Alberta
14:00-15:30	EMG Atelier 4	Salon 19
14:00-17:30	Cours sur les soins d'urgence en neurologie	Salon 3
14:00-17:30	Cours sur l'épilepsie	Jasper Room Fairmont
14:00-17:30	Cours sur la douleur neuropathique	Drawing Room Fairmont
16:00-17:30	EMG Atelier 1	Salon 15
16:00-17:30	EMG Atelier 2	Salon 16
16:00-17:30	EMG Atelier 4	Salon 19
14:00-17:30	Cours sur l'accident vasculaire cérébral	Salon 2
17:30-19:00	Ouverture de l'exposition (réception des exposants)	Salons 8,9,10 & 11
19:00-21:00	Réception des Présidents	Salle de bal Empire/Hall/Terrace Fairmont

Code des couleurs

Assemblée générale annuelle (AGA)
Association canadienne de neurologie pédiatrique (ACNP)
Fédération des sciences neurologiques du Canada (FSNC)
Journal canadien des sciences neurologiques (JCSN)
Société canadienne de neurologie (SCN)
Société canadienne de neurochirurgie (SCNCH)
Société canadienne de neurophysiologie clinique (SCNC)

Les lettres en bleu désignent des événements du programme scientifique.

Les lettres en noir, des rencontres à caractère commercial ou autre.

Jeudi 21 juin 2007

06:15	Pour le plaisir, course/marche ACIISN pour la recherche neuroscientifique en sciences infirmières. Consultez www.cann.ca pour plus de renseignements	
07:00-18:30	Inscription	Meeting Level Foyer
07:30-18:00	Salle de préparation pour les conférenciers	Salon 7
07:30-08:30	Réunion de la Ligue canadienne contre l'épilepsie	Salon 18
07:30-08:30	Groupe canadien des soins d'urgence en neurologie	Salon 17
07:30-08:30	Sociétés affiliées à la FSNC	Salon 1
07:00-08:30	Conseil canadien d'enregistrement des technologistes en EEG (CCETE)	Salon 19
08:30-10:00	S. plénière – Neurologie SCN, CACN & SCNC	Salon 12
08:30-10:00	S. plénière – Neurochirurgie SCNCH	Salon 2
10:15-12:30	Communications orales libres (Neurochirurgie générale 1)	Salon 4
10:15-12:30	Communications orales libres (SEP)	Salon 2
10:15-12:30	Communications orales libres (Neurologie AVC)	Salon 3
10:15-12:30	Communications orales libres (Neurologie générale)	Salon 12
10:15-12:30	Communications orales libres (Neuropédiatrie générale)	Salon 5 & 6
10:15-12:30	Communications orales libres (Epilepsie & EEG)	Salon 13/14
12:30-14:00	Déjeuner dans la salle des expositions et Communications par affiches et exposition	Salons 8,9,10 & 11
14:00-16:30	Communications orales libres (Neurochirurgie générale 2)	Salon 4
14:00-16:30	Communications orales libres (Colonne vertébrale)	Salon 2
14:00-16:30	Communications orales libres (Neuro-oncologie)	Salon 3
14:00-16:30	Communications orales libres (Chirurgie vasculaire cérébrale)	Salon 12
14:00-16:30	Communications orales libres (Neuromusculaire)	Salon 5 & 6
14:00-16:30	Communications orales libres (Epilepsie de l'enfant)	Salon 13/14
14:00-16:30	Communications orales libres (Soins intensifs)	Salon 15/16
16:30-18:00	Groupe canadien de recherche neuromusculaire chez l'enfant	Salon 1
16:30-18:00	Communications affichées électroniques & visite de l'exposition	Salons 8,9,10 & 11
17:00-18:00	Réunion de la Fondation de la SCN	Salon 19
18:00-19:00	Soirée des résidents	Salon 5/6
19:00	D. des présidents	Hall D

Vendredi 22 juin 2007

07:00-13:30	Inscription	Meeting Level Foyer
07:30-18:00	Salle de préparation pour les conférenciers	Salon 7
07:30-08:30	AGA de la Société canadienne des céphalées	Salon 20
07:00-08:30	AGA de la SCNC	Salon 6
07:00-08:30	AGA de la Soc. can. de neurochirurgie (SCNCH)	Salon 13/14
07:00-08:30	AGA de la Soc. can. de neurologie (SCN)	Salon 15/16
08:30-09:30	Conférence par l'invité de marque	Salon 12
09:30-09:50	Rapport de la CCSCNP	Salon 12
09:50-10:00	Présentation du Prix Eminent relecteur de manuscrits et introduction du nouveau rédacteur en chef du JCSN	Salon 12
09:30-15:00	Tour des communications affichées et des expositions	Salons 8,9,10 & 11
10:15-12:00	Discussion de cas cliniques	Salon 12
10:30-12:00	Réunion de la CCSCNP	Salon 17 & 18
12:00-13:30	Déjeuner dans la salle d'exposition et tour des communications affichées	Salons 8,9,10 & 11
12:00-13:30	Neurochirurgie, comité du Collège royal	Salon 17 & 18
13:30-17:00	Cours: céphalées	Salon 2
13:30-17:00	Cours: quoi de neuf en neurochirurgie	Drawing Room Fairmont
13:30-17:00	Cours: EEG	Salon 4
13:30-17:00	Cours: Démence	Salon 3
13:30-17:00	Cours: SEP	Salons 5/6
13:30-17:00	Cours: Quoi de neuf en neurologie	Wedgewood Fairmont
13:30-17:00	Cours: neuromusculaire	Salon 12
17:00-18:00	Réunion du conseil des FSNC/JCSN	Salon 17 & 18
17:00-22:00	Réunion du Groupe "Canadian Headache Outpatient Registry and Database"	Salon 19

Samedi 23 juin 2007

08:00-09:30	Assemblée générale annuelle de Pensez d'abord Canada	Salle Winterlake, Hôtel Sutton Place
09:30-12:30	Réunion des sections de Pensez d'abord Canada	Salle Winterlake, Hôtel Sutton Place

Cours de révision en neurobiologie

Salon 4 - 08:00-17:00

Cours généreusement financé par une subvention sans condition à but éducatif de la Fondation de la Société canadienne de neurologie.

Président: Jack Jhamandas

Objectifs du cours: à l'issue de ce cours les participants pourront:

1. Décrire la neurobiologie de la maladie neurodégénérative.
2. Réfléchir à la base neurale du comportement rythmique du SNC.
3. Exposer clairement la neuroimmunologie et la neuroimagerie de la SEP.
4. Faire le point sur les mécanismes et la physiopathologie de l'épilepsie.

Public visé: cliniciens de disciplines connexes de neurosciences (neurologues, neurochirurgiens, neurophysiologistes, etc.) et personnes en cours de formation (résidents, chercheurs, etc.)

MÉCANISMES FONDAMENTAUX DES MALADIES NEURODÉGÉNÉRATIVES

08:00	Neurobiologie de la famille de la protéine prion	David Westaway, (Edmonton, AB)
08:45	Base moléculaire de la perte de mémoire dans les modèles transgéniques de la maladie d'Alzheimer	
		Karen Hsiao Ashe, (Minnesota, USA)
09:30	Discussion	
09:45	Pause	

BASE NEURALE DU COMPORTEMENT RYTHMIQUE DANS LE SNC

10:00	Contrôle central de la rythmogenèse respiratoire	John Greer, (Edmonton, AB)
10:45	Progrès récents dans la neurobiologie de la marche	Keir Pearson, (Edmonton, AB)
11:30	Discussion	
12:00	Pause déjeuner	

INFORMATIONS RÉCENTES SUR LA NEUROIMMUNOLOGIE ET LA NEUROIMAGERIE DE LA SCLÉROSE EN PLAQUES

13:15	Autoimmunité dans la sclérose en plaques: une épée à double tranchant	Fabrizio Giuliani, (Edmonton, AB)
14:00	Biomarqueurs IRM de pathologie dans la Sclérose en plaques	Ross Mitchell, (Calgary, AB)
14:45	Discussion	

EPILEPSIE: CONNAISSANCES EN PHYSIOPATHOLOGIE

15:00	Etude de l'anatomie fonctionnelle du système limbique par l'épilepsie du lobe temporal et l'IRM	
		Don Gross, (Edmonton, AB)
15:45	Mécanismes de l'Epilepsie	William Colmers, (Edmonton, AB)
16:30	Discussion et évaluation	

SLA: stratégies pour qualité de vie/qualité des soins

Salon 3 - 08:30-17:00

Présidents: David Cameron, Cathy Martin**Objectifs du cours:** à l'issue de ce cours les participants sauront:

1. Décrire les spécificités cliniques et physiopathologiques actuelles de la SLA.
- Reconnaître et appliquer les stratégies pouvant améliorer la fonction et la qualité de vie des personnes ayant une SLA.
2. Prouver qu'ils comprennent les initiatives de recherche et les découvertes dans le domaine de la SLA.

Public visé: journée entière de séances interactives avec patients, soignants, personnel paramédical, neurologues, physiatres, organismes d'aide communautaire d'aide et de soutien: tour d'horizon complet des sujets d'actualité dans le domaine de la SLA, y compris diagnostic et recherche, prise en charge et sensibilisation.

08:30 Inscription

09:00 Accueil.....David Cameron, (Toronto, ON); Cathy Martin, (Edmonton, AB)

SÉANCE I PRÉSENTATION PLÉNIÈRE - PRÉSIDENTS: COLLEEN O'CONNELL, SANJAY KALRA09:10 **Mise à jour – Progrès en soins cliniques**Michael Strong, (London, ON)09:35 **Mise à jour – Progrès en sciences fondamentales**Denise Figlewicz, (Toronto, ON)

10:00 Séance questions et réponses

10:20 Pause

SÉANCE II PRÉSENTATION EN TABLE RONDE - PRÉSIDENTE: TESSA GORDON10:40 **Point de vue du patient**TBC11:00 **Société SLA de l'Alberta**TBC11:20 **Facteurs de risques environnementaux**Chris White, (Calgary, AB)11:40 **Gérer l'excès de salive: médicaments, botox, irradiation**Stuart Cleary, (Edmonton, AB)

12:00 Séance questions et réponses

12:15 Pause déjeuner

SÉANCE III ATELIERS13:30 **Patients, soignants et professionnels des soins de santé** - animateur de discussion: Mary Hatcher(1) **Directives avancées**Melinda Hatfield, SW and Jane Rivest, (Calgary, AB)(2) **Quelle est l'utilité des visites à domicile et de télésanté?**Pat Carey, (Edmonton, AB)(3) **Sexualité**Colleen O'Connell, (Fredericton, NB)13:30 **Médecins et chercheurs** - animateur de discussion: Tim Doherty(1) **Rôle de l'EMG, de l'estimation de nombre d'unités motrices, et de la stimulation transcrânienne dans le diagnostic, le suivi et les essais thérapeutiques**Ming Chan, (Edmonton, AB)(2) **Prise en charge des symptômes**Sanjay Kalra, (Edmonton, AB)

15:00 Pause

SÉANCE IV - PRÉSIDENTS: DAVID CAMERON, MARY HATCHER15:15 **Parler d'espoir avec les patients SLA et leurs familles**Wendy Johnston, (Edmonton, AB)15:55 **Mots de conclusion et remplissage des feuilles d'évaluation**David Cameron, (Toronto, ON); Mary Hatcher, (Halifax, NS)

17:00 Discussion et évaluation

Jour de neuropédiatrie - Controverses et progrès en neurologie néonatale

Salon 2 - 08:30-17:00

Présidents: Jerome Yager, Steve Miller

- Objectifs du cours:** à l'issue de ce symposium les participants pourront:
1. Indiquer les causes les plus fréquentes de lésion neurologique chez le nouveau-né
 2. Décrire les conséquences neurologiques de la maladie cardiaque congénitale et être au courant des nouvelles techniques de détection
 3. Comprendre les causes et les conséquences des naissances prématurées
 4. Exposer les méthodes nouvelles d'intervention thérapeutique chez le nouveau-né qui a une lésion du cerveau.

Public visé: neuropédiatres, pédiatres, néonatalogistes, résidents, infirmier(ère)s.

08:30	Introduction	
08:40	Ischémie cérébrale néonatale: neuroimagerie comme base pour un traitement rationnel par les cellules souches	Stephen Ashwal, (Loma Linda, CA, USA)
09:40	Convulsions néonatales – Est-ce qu'elles abîment le cerveau?	Lionel Carmant, (Montreal, QC)
10:20	Pause	
10:50	Neuroimagerie de pointe et le cerveau du nouveau-né	Steve Miller, (Vancouver, BC)
11:30	Nouveau regard sur le sort des nourrissons qui ont une maladie cardiaque congénitale	Annette Majnemer, (Montreal, QC)
12:10	Déjeuner	
13:30	Est-ce que l'inflammation a de l'importance?	Guillaume Sebire, (Sherbrooke, QC)
14:10	Quel sort attend le bébé grand prématuré. Quoi de neuf et où allons-nous?	Charlene Robertson, (Edmonton, AB)
14:50	Interventions thérapeutiques chez le nouveau-né: avons-nous quelque chose à offrir?	Jerome Yager, (Edmonton, AB)
15:40	Pause	
16:00	Etude de cas cliniques	
16:30	Discussion et évaluation	

Séance épilepsie et vidéo

Salon 4 - 18:00-20:00

Président: Richard McLachlan

- Objectifs du cours:** à l'issue de ce symposium, les participants pourront:
1. Comprendre comment utiliser au mieux les vidéos pour faire le diagnostic d'événements paroxystiques
 2. Etudier les caractéristiques électrocliniques des convulsions neuro-métaboliques
 3. Revoir l'utilisation des vidéos avec les enfants

Public visé: résidents, fellows et étudiants, neurologues pour adultes et pour enfants, infirmier(ère)s de neurologie et technologistes d'EEG.

18:00	Caractéristiques électrocliniques des causes neuro-métaboliques de l'épilepsie	Mary Connolly, (Vancouver, BC)
18:15	Discussion	
18:25	Epilepsie au pays de cocagne	Sam Wiebe, (Calgary, AB)
18:45	Discussion	
18:55	Epilepsie chez l'enfant	Sharon Whiting, (Ottawa, ON)
19:15	Discussion	
19:25	Quelque chose d'intéressant pour chacun	Richard McLachlan, (London, ON)
19:55	Discussion et évaluation	

Prise en charge des mouvements anormaux: des médicaments à l'intervention chirurgicale

Wedgewood Fairmont - 18:00-20:00

Cours généreusement financé par une subvention sans condition à but éducatif de Prestwick Pharma.

Président: Richard Camicioli

- Objectifs du cours:** à l'issue de ce symposium, les participants pourront:
1. Comprendre quelles approches scientifiquement fondées sont utilisables pour traiter la maladie de Parkinson
 2. Reconnaître qui peut être candidat à une évaluation chirurgicale du parkinsonisme et des mouvements anormaux hyperkinétiques en ayant pleinement conscience des résultats et des risques
 3. Evaluer le traitement scientifiquement fondé pour la chorée, la dyskinésie et la dystonie

Public visé: TBC

18:00	Prise en charge médicale du parkinsonisme	Oksana Suchowersky, (Calgary, AB)
18:25	Prise en charge chirurgicale du parkinsonisme	Christopher Honey, (Vancouver, BC)
18:55	Prise en charge médicale de la chorée et de la dystonie	Mandar Jog, (London, ON)
19:25	Chirurgie des mouvements anormaux hyperkinétiques	Andres Lozano, (Toronto, ON)
19:55	Discussion et évaluation	

GROUPES DE PRESSION SPECIALISES

18:00-20:00

18:00	SLA	Jasper Room Fairmont	Angela Genge
18:00	NEUROMUSCULAIRE	Salon 3	Mike Nicolle
18:00	ENSEIGNEMENT AUX RESIDENTS DE NEUROCHIRURGIE	Drawing Room Fairmont	Brian Toyota
18:00	ENSEIGNEMENT DE NEUROLOGIE AUX ETUDIANTS	Salon 13 & 14	Kevin Busche

Séance plénière d'ouverture: progrès scientifiques et techniques dans le domaine des neurosciences cliniques

Salon 12 -
08:30-10:30

Présidents: Mark Hamilton, Andrew Kirk

- Objectifs du cours:** À l'issue de ce symposium les participants pourront :
1. Discuter les techniques contemporaines d'imagerie dans les troubles neurologiques
 2. Exposer clairement les possibilités de traitement neurochirurgical dans les troubles psychiatriques
 3. Décrire l'utilisation de techniques avancées de neuro-imagerie dans le cas d'une lésion traumatique du cerveau chez un enfant

08:30	Accueil et Introduction	
08:45	Techniques contemporaines d'imagerie dans les troubles neurologiques	Walter Kucharczyk, (Toronto, ON)*
09:20	Approches contemporaines neurochirurgicales dans le traitement des troubles psychiatriques.	Andres Lozano, (Toronto, ON)*
09:55	Conférence Tibbles – le cerveau qui paraît normal n'est pas normal – Utilisation des techniques de pointe de neuroimagerie	Steve Ashwal, (Loma Linda, CA, USA)*

* Parraine par le College royal des medecins et chirurgiens du Canada.

Présentation plénière choisie par le Président

Salon 12 - 10:45-12:15

Douleur neuropathique - Physiopathologie, prévention et prise en charge

Drawing Room Fairmont - 14:00-17:30

Cours généreusement financé par une subvention sans condition à but éducatif de Pfizer Inc.

Président: Dwight Moulin

- Objectifs du cours:** à l'issue de ce cours les participants pourront:
1. Comprendre la physiopathologie de la douleur neuropathique pour la prendre comme base de traitement
 2. Avoir une approche basée sur des faits prouvés pour prendre en charge la douleur neuropathique
 3. Reconnaître la valeur de substances nouvelles dans la prévention et la prise en charge de la douleur neuropathique

Public visé: médecins de famille, neurologues, neurochirurgiens et infirmier(ère)s praticien(ne)s cliniques.

14:00	Prévalence et physiopathologie de la douleur neuropathique	Dwight Moulin, (London, ON)
14:30	Discussion	
14:45	Néuralgie post-herpétique - bilan et prise en charge	Peter Watson, (Toronto, ON)
15:15	Discussion	
15:30	Pause alimentaire	
15:45	Consignes basées sur des faits prouvés pour prendre en charge la douleur neuropathique	Dwight Moulin, (London, ON)
16:30	Substances nouvelles pour prendre en charge la douleur neuropathique	John Clark, (Calgary, AB)
17:00	Discussion et évaluation	

Cours sur la colonne vertébrale – Triage et prise en charge du patient qui a une myélopathie spondylotique cervicale

Wedgewood Fairmont - 14:00-17:30

Président: Eric Massicotte

- Objectifs du cours:** à l'issue de ce symposium les participants pourront:
1. Saisir et comprendre la difficulté d'évaluer les patients qui ont une myélopathie. Indiquer les indices qui peuvent aider à établir un diagnostic correct.
 2. Discuter les options de prise en charge de ces malades
 3. Faire le point sur les approches chirurgicales spécifiques de la spondylite
 4. Expliquer clairement le rôle des techniques peu invasives et reconstructives chez ces patients

Public visé: les neurologues et neurochirurgiens en formation ou à la pratique bien établie ainsi que les prestataires de soins de santé peuvent tirer bénéfice de cette séance.

14:00	Difficultés de diagnostic: quels sont les indices cliniques ?	<i>Robert Chen, (Toronto, ON)</i>
14:15	Discussion	
14:30	Histoire naturelle de la spondylose et de la myélopathie	<i>Richard Fox, (Edmonton, AB)</i>
14:45	Discussion	
15:00	Approches antérieures dans la spondylose cervicale	<i>Steve Casha, (Calgary, AB)</i>
15:15	Discussion	
15:30	Approches postérieures dans la spondylose cervicale	<i>Ramesh Sahjpaul, (Vancouver, BC)</i>
15:45	Discussion	
16:00	Pause	
16:15	Rôle des techniques peu invasives	<i>Sean Christie, (Halifax, NS)</i>
16:30	Discussion	
16:45	Stratégies de reconstruction complexe	<i>Eric Massicotte, (Toronto, ON)</i>
17:00	Issue fonctionnelle de la myélopathie spondylosique cervicale	<i>Sukhuinder Kalsi-Ryan, (Toronto, ON)</i>
17:10	Discussion et évaluation	

Cours d'électromyographie clinique

(voir ci-dessous pour l'attribution des salles) - 14:00-17:30

Les ateliers 1, 2, et 4 se tiendront au Shaw Centre. L'atelier 3 se tiendra à l'Université de l'Alberta [le transport n'est pas assuré]. Seuls les ateliers 1, 2, et 4 auront 2 séances.

Présidents: Ming Chan, Joseph Chu

- Objectifs du cours:** à l'issue de ce symposium les participants pourront:
1. Comprendre l'approche électrodiagnostique pour faire le bilan de la SLA et des syndromes lui ressemblant
 2. Faire le point sur l'EMG d'une seule fibre
 3. Décrire les tests électrodiagnostiques et identifier les nerfs rarement étudiés du membre supérieur
 4. Discuter les perles et les pièges de l'EMG en particulier pour les muscles inhabituels

Public visé: neurologues, EMGrapheurs, fellows et résidents de neurologie, physiologistes et techniciens d'EMG.

14:00 &	
16:00	Atelier 1: approche électrodiagnostique pour le bilan de la SLA et des syndromes lui ressemblant Salon 15Chris White, (Calgary, AB)
14:00 &	
16:00	Atelier 2: EMG d'une seule fibre Salon 16 Michael Nicolle, (London, ON)
14:00	Atelier 3: identification anatomique et test électrodiagnostique de nerfs rarement étudiés du membre supérieur Université de l'Alberta Lalith Satkunam, (Edmonton, AB); Ian Grant, (Halifax, NS); Michael Morhart, (Edmonton, AB)
14:00 &	
16:00	Atelier 4: EMG de muscles inhabituels et quel intérêt ils ont dans l'électrodiagnostic en neurologie Salon 19 Jasper Daube, (Rochester, MN, USA)

Cours sur l'accident vasculaire cérébral

Salon 2 - 14:00-17:30

Cours généreusement financé par une subvention sans condition à but éducatif de Sanofi-aventis/Bristol-Myers Squibb.

Présidents: Khurshid Khan, Ashfaq Shuaib

- Objectifs du cours:** à l'issue de ce cours les participants pourront:
1. Analyser les mécanismes physiopathologiques contribuant à l'athérosclérose et aux divers types d'attaques cérébrales.
 2. Etudier en détail les diverses technologies nouvelles d'imagerie aidant à établir un diagnostic en présence d'une attaque cérébrale
 3. Trouver les meilleures options thérapeutiques pour des sous-types spécifiques d'accident vasculaire cérébral
 4. Juger de manière critique les nouvelles thérapies d'apparition récente dans le domaine de la maladie vasculaire cérébrale.

Public visé: TBC

14:00	Prise en charge de l'accident vasculaire cérébral aiguPhilip Teal, (Vancouver, BC)
14:25	Discussion
14:35	Prévention de l'AVCAshfaq Shuaib, (Edmonton, AB)
15:00	Discussion
15:10	Neuroimagerie (CT/IRM) dans l'AVC aiguKen Butcher, (Edmonton, AB)
15:35	Discussion
15:40	Pause
15:50	Hémorragie intracérébraleMatthew Hogan, (Ottawa, ON)
16:15	Discussion
16:25	Approche neurochirurgicale des conditions cérébrovasculaires "asymptomatiques" (y compris maladie de la carotide, anévrismes, et malformations vasculaires)Max Findley, (Edmonton, AB)
16:50	Discussion
17:00	Procédures endovasculairesMichael Chow, (Edmonton, AB)
17:25	Discussion et évaluation

Cours sur l'épilepsie: épilepsie réfractaire*Salle Jasper Fairmont - 14:00-17:30***Président:** Richard Wennberg**Objectifs du cours:** à l'issue de ce symposium, les participants pourront:

1. Reconnaître les patients présentant une épilepsie réfractaire
2. Evaluer le fardeau qu'est l'épilepsie réfractaire au Canada
3. Comprendre quand et pourquoi envoyer les patients à des centres spécialisés pour l'épilepsie
4. Comprendre les tests à faire avant la chirurgie et les résultats de la chirurgie de l'épilepsie chez l'adulte et l'enfant.

Public visé: neurologues et neurochirurgiens de l'adulte et de l'enfant, résidents et fellows de neurologie et de neurochirurgie, épileptologistes et personnel paramédical spécialisé en épilepsie.

14:00	Introduction	
14:10	Epilepsie réfractaire de l'adulte: vue d'ensemble et explorations cliniques	Don Gross, (Edmonton, AB)
14:30	Discussion	
14:35	Epilepsie réfractaire de l'adulte: épidémiologie et fardeau économique:	Sam Wiebe, (Calgary, AB)
14:55	Discussion	
15:00	Epilepsie réfractaire de l'adulte: chirurgie	Andrew Parrent, (London, ON)
15:20	Discussion	
15:25	Pause	
15:40	Neuroimagerie dans l'épilepsie réfractaire de l'adulte	Andrea Bernasconi, (Montreal, QC)
16:00	Discussion	
16:05	Construction d'un centre pluridisciplinaire spécialisé pour l'épilepsie	Taufik Valiente, (Toronto, ON)
16:25	Discussion	
16:30	Epilepsie réfractaire de l'enfant: vue d'ensemble et explorations cliniques	Mary Connolly, (Vancouver, BC)
16:50	Discussion	
16:55	Epilepsie réfractaire de l'enfant: chirurgie	James Rutka, (Toronto, ON)
17:15	Discussion et évaluation	

Cours sur les soins intensifs neurologiques*Salon 3 - 14:00-17:30***Présidents:** Draga Jichici, Jeanne Teitelbaum**Objectifs du cours:** à l'issue de ce symposium les participants sauront:

1. Appliquer un traitement hypothermique à certains groupes de patients
2. Traiter de manière efficace l'état de mal épileptique
3. Comprendre les imitations de mort cérébrale
4. Evaluer et diagnostiquer la faiblesse neuromusculaire dans le service de soins intensifs
5. Analyser les techniques nouvelles pour diagnostiquer et prendre en charge le traumatisme crânien
6. Faire le pronostic du résultat après un arrêt cardiaque

Public visé: neurologues en pratique clinique, neurochirurgiens, médecins intensivistes, résidents et infirmier(ère)s.

14:00	Prise en charge de l'état de mal épileptique	Martin Savard, (London, ON)
14:30	Hypothermie en soins intensifs neurologiques: quand l'utiliser	Draga Jichici, (Hamilton, ON)
15:15	Approches nouvelles de la faiblesse musculaire généralisée dans les unités de soins intensifs.	Charles Bolton, (Kingston, ON)
15:45	Mort cérébrale: ou non?	Jeanne Teitelbaum, (Montreal, QC)
16:15	Quoi de neuf dans la prise en charge du traumatisme crânien: la microdialyse	David Zygun, (Calgary, AB)
16:45	Discussion et évaluation	

Séance plénière: SNC, ACNP, et SCNC neurologie

Salon 12 - 08:30-10:00

Président: Richard Desbiens

- Objectifs du cours:** à l'issue de ce symposium les participants sauront:
1. Discuter les faits nouveaux dans la prise en charge des myopathies inflammatoires
 2. Comprendre les causes de la "paralysie cérébrale infantile", le déroulement de la vie des personnes nées avec cette maladie, et les grandes lignes pour la prise en charge de ces patients.

- 08:30 Accueil et introduction
- 08:35 **Conférence Gloor - Myopathies inflammatoires - Faits nouveaux**Tony Amato, (Boston, MA, USA)
- 09:20 **Conférence Richardson - Une cible en mouvement: les difficultés contemporaines dans le domaine de la paralysie générale infantile tout au long de l'existence**Michael Shevell, (Montreal, QC)

Séance plénière: SCNCH neurochirurgie

Salon 2 - 08:30-10:00

Président: Derek Fewer

- Objectifs du cours:** à l'issue de ce symposium les participants pourront:
1. Comprendre les principes de la neurochirurgie endoscopique
 2. Analyser les résultats et les complications de la neurochirurgie endoscopique
 3. Discuter le traitement chirurgical et endovasculaire des fistules artério-veineuses dures.

- 08:30 Accueil et introduction
- 08:35 **Conférence Penfield - Principes de neurochirurgie endoscopique: résultats et complications sur dix ans et 700 patients.**Amin Kassam, (Pittsburgh, PA, USA)
- 09:20 **Prise en charge chirurgicale et endovasculaire des fistules artério-veineuses intracrâniennes et rachidiennes**Charles Haw, (Vancouver BC)

Communications orales libres (6 simultanément)

Salon 2,3,4,5,6 & 12, 13,14 - 10:15-12:30

Déjeuner / communications par affiches électroniques et tour de l'exposition Salon 8,9,10,11 - 12:30-14:00

Communications orales libres (7 simultanément)

Salon 2,3,4,5,6 & 12,13,14,15,16 - 14:00-16:30

Communications par affiches électroniques et tour de l'exposition

Salon 8,9,10,11 - 16:30-18:00

Conférence par l'invité de marque

Salon 12 - 08:30-09:30

Séance plénière généreusement financée par une subvention sans condition à but éducatif du Journal canadien des Sciences neurologiques.

- Objectifs du cours:** à l'issue de ce symposium les participants sauront:
1. Analyser l'histoire de l'évolution de la neurochirurgie et de la neurologie.
 2. Discuter le fardeau que constituent la maladie, les troubles et les lésions neurologiques au Canada

08:30 Accueil et introduction

08:40 **De Osler à Cushing – essor de la médecine, essor de la neurochirurgie** Michael Bliss, (Toronto, ON)

Compte-rendu de la CCSCNP

Salon 12 - 09:30-09:50

09:30 **Le fardeau que constituent la maladie, les troubles et les lésions neurologiques au Canada** Charles Tator, (Toronto, ON); Garth Bray, (Montreal, QC)

Remise du prix JCSN 2007 Eminent relecteur de manuscrits

Salon 12 - 09:50-10:00

Communications par affiches électroniques et tour de l'exposition

Salon 8,9,10,11 - 09:50-10:15

Discussion de cas cliniques

Salon 12 - 10:15-12:00

Présidents: Richard Camicioli, Michael Hill

- Objectifs du cours:** à l'issue de ce symposium les participants sauront:
- Utiliser le format de la discussion de cas cliniques pour une discussion multidisciplinaire et interactive de malades.

Cas neurologique: Taim Muayqil, (Zaeem Siddiqui, Richard Camicioli)

Dépression et déficit cognitif léger

Cas neurochirurgical: Fred Lam, (Matt Wheatley, Wendy Johnston, Ted Roberts)

La maladie du neurone moteur et le neurochirurgien

Cas neuro-pédiatrique: Vijay Ramaswamy, (Lawrence Richer, Hanna Kolski)

Kystes bilatéraux et hémorragie sous-durale spontanée

Déjeuner / Communications par affiches électroniques et tour de l'exposition Salon 8,9,10,11 - 12:00-13:30

Cours sur les céphalées

Salon 2 - 13:30-17:00

Président: Marek Gawel

- Objectifs du cours:** à l'issue de ce symposium les participants sauront:
1. Evaluer les facteurs entrant en jeu et l'étiologie de la céphalée chronique chez leurs patients
 2. Unifier leurs connaissances en physiopathologie et les causes pharmacologiques de la céphalée chronique
 3. Etablir un plan de traitement pluridisciplinaire
 4. Choisir les thérapies pharmacologiques et non pharmacologiques adéquates pour la céphalée chronique

Public visé: neurologues généraux

13:30	Accueil	Marek Gawel, (Toronto, ON)
13:45	Progrès récents en physiopathologie, y compris les données récentes TEP	Michael Aubé, (Montreal, QC)
14:00	Lésions du FOP et de la substance blanche du SNC dans la migraine: concepts actuels	Werner Becker, (Calgary, AB)
14:15	Céphalée chronique du type céphalée de tension	Michael Aubé, (Montreal, QC)
14:45	Migraine transformée	Lara Cooke, (Calgary, AB)
15:15	Céphalée du type céphalée de tension chez l'enfant	Shashi Seshia, (Saskatoon, SK)
15:30	Céphalée post-traumatique	Marek Gawel, (Toronto, ON)
16:00	Céphalée en grappe chronique et céphalées trigéminales autonomes	Suzanne Christie, (Ottawa, ON)
16:30	Discussion et évaluation	

Cours: quoi de neuf en neurochirurgie

Drawing Room Fairmont - 13:30-17:00

Président: Rick Moulton

- Objectifs du cours:** à l'issue de ce symposium les participants sauront :
1. Analyser les différentes possibilités de prise en charge de patients ayant une hydrocéphalie et les résultats
 2. Identifier les nouveaux traitements et les options de prise en charge des malformations artério-veineuses (MAV)
 3. Exposer clairement les récentes options de traitement et les résultats s'y rapportant dans le traumatisme grave du cerveau
 4. Discuter les traitements nouveaux et les options de prise en charge de patients qui ont un gliome
 5. Choisir des stratégies de prise en charge adéquates pour les métastases spinales
 6. Comparer les résultats et les options de traitement pour l'épilepsie du lobe temporal

Public visé: neurochirurgiens, résidents de neurochirurgie, neurologues

13:30	Hydrocéphalie	Ab Kulkarni, (Toronto, ON)
14:00	MAVs	Ian Fleetwood, (Halifax, NS)
14:30	Traumatisme grave du cerveau	Rick Moulton, (Ottawa, ON)
15:00	Gliomes	Ian Parney, (Calgary, AB)
15:30	Métastases spinales	Daryl Fourney, (Saskatoon, SK)
16:00	Epilepsie du lobe temporal	Matt Wheatley, (Edmonton, AB)
16:30	Discussion et évaluation	

Cours sur l'EEG

Salon 4 - 13:30-17:00

Président: Seyed Mirsattari

- Objectifs du cours:** à l'issue de ce symposium les participants sauront:
1. Reconnaître les caractéristiques EEG normales et anormales habituellement rencontrées chez les patients qui ont une épilepsie
 2. Analyser les caractéristiques EEG du nouveau-né et de l'enfant
 3. Saisir les bases de la technologie EEG, y compris la technologie numérique

Public visé: neurologues, résidents de neurologie et neuro-pédiatres

13:30	EEG du nouveau-né - normal et anormal	Eli M. Mizrahi, (Houston, TX, USA)
14:15	Discussion	
14:20	EEG de l'enfant	Warren T. Blume, (London, ON)
15:05	Discussion	
15:10	Pause	
15:15	EEG de l'adulte - normal et chez les patients qui ont une épilepsie	Richard S. McLachlan, (London, ON)
16:00	Discussion	
16:05	Bases de la technologie EEG, l'accent étant mis sur les techniques numériques	Susan Rahey, (Halifax, NS)
16:50	Discussion et évaluation	

Cours sur la démence

Salon 3 - 13:30-17:00

Cours généreusement financé par une subvention sans condition à but éducatif de Pfizer Inc.

Président: Gabriel Léger

- Objectifs du cours:** à l'issue de ce symposium les participants sauront:
1. Reconnaître les présentations habituelles des démences non-Alzheimer (mixte/vasculaire, à corps de Lewy/maladie de Parkinson, et fronto-temporale), et comment elles diffèrent de la maladie d'Alzheimer typique (MA)
 2. Utiliser au chevet du patient des tests cognitifs sensibles qui aident à différencier ces démences de la MA.
 3. Diagnostiquer ces démences à partir des critères du consensus diagnostique actuel.
 4. Déterminer un plan de traitement adapté à la démence non-Alzheimer, incluant les médicaments à utiliser et ceux à éviter

Public visé: neurologues

13:30	De la démence vasculaire au déficit cognitif vasculaire	Christian Bocti, (Montreal, QC)
14:15	Discussion	
14:45	Démence de la maladie de Parkinson et maladie à corps de Lewy	Céline Chayer, (Montreal, QC)
15:30	Discussion	
15:45	Diagnostic et prise en charge des démences fronto-temporales	Gabriel Léger, (Montreal, QC)
16:30	Discussion et évaluation	

Cours sur la SEP

Salon 5/6 - 13:30-17:00

Président: Kenneth Warren

- Objectifs du cours:** à l'issue de ce symposium les participants sauront:
1. Comprendre l'ampleur et la nature de la SEP dans la société canadienne
 2. Discuter les changements qualitatifs et quantitatifs dans le liquide céphalo-rachidien et les caractéristiques neuropathologiques de la SEP
 3. Analyser comment les progrès récents en pathologie et en pharmacologie affectent la prise en charge de la SEP

Public visé: neurologues généraux et neurologues spécialisés en SEP.

13:30	Progrès IRM	Derrick Emery, (Edmonton, AB)
13:45	Discussion	
13:50	Changements démographiques et tendances cliniques	Sharon Warren, (Edmonton, AB)
14:05	Discussion	
14:10	Qualité de vie	Karen Turpin, (Edmonton, AB)
14:25	Discussion	
14:30	Variabilité neuropathologique	Lothar Resch, (Edmonton, AB)
14:45	Discussion	
14:50	Pause	
15:10	Mort neuronale et neuroprotection	Fabrizio Giuliani, (Edmonton, AB)
15:25	Discussion	
15:30	Nouvelles tendances thérapeutiques	Greg Blevins, (Edmonton, AB)
15:45	Discussion	
15:50	Neurovirologie	Chris Power, (Edmonton, AB)
16:05	Discussion	
16:10	Expériences de patients hébergés au long cours	Garry Wheeler, (Edmonton, AB)
16:25	Discussion	
16:30	Anticorps dans le LCR	Ingrid Catz, (Edmonton, AB)
16:45	Discussion et évaluation	

Cours: quoi de neuf en neurologie?

Wedgewood Fairmont - 13:30-17:00

Président: Ashfaq Shuaib

- Objectifs du cours:** à l'issue de ce symposium les participants pourront:
1. Discuter des options nouvelles de traitement et de prise en charge de la SLA
 2. Analyser les progrès faits dans le traitement des infections du SNC
 3. Décrire les options de traitement et les nouveaux traitements des tumeurs du SNC
 4. Expliquer clairement les progrès faits dans le domaine de la maladie neuromusculaire
 5. Décrire les options récentes dans le traitement de l'hémorragie intracrânienne

Public visé: neurologues, résidents de neurologie, infirmier(ère)s, fellows et neurochirurgiens.

13:30	Introduction	
13:40	Quoi de neuf dans le neuromusculaire?	Douglas Zochodne, (Calgary, AB)
14:15	Discussion	
14:20	Quoi de neuf dans les infections?	Chris Power, (Edmonton, AB)
14:55	Discussion	
15:00	Quoi de neuf dans l'hémorragie intracrânienne?	Ashfaq Shuaib, (Edmonton, AB)
15:35	Discussion	
15:40	Quoi de neuf en SLA?	Mike Strong, (London, ON)
16:15	Discussion	
16:20	Quoi de neuf dans les tumeurs du SNC?	Ian Parney (Calgary, AB)
16:55	Discussion et évaluation	

Cours sur le neuromusculaire

Salon 12 - 13:30-17:00

Président: Mike Nicolle

- Objectifs du cours:** à l'issue de ce symposium les participants sauront:
1. Différencier et prendre en charge les neuropathies de compression fréquentes et rares
 2. Diagnostiquer les troubles affectant les plexus brachial et lombo-sacré
 3. Expliquer la relation entre la physiologie de base de la fonction nerveuse et la pathologie des nerfs périphériques dans le diabète.
 4. Expliquer clairement les manifestations cliniques des neuropathies diabétiques.
 5. Combiner leurs connaissances sur les mécanismes génétiques de la dystrophie myotonique congénitale avec les manifestations cliniques et les tests diagnostiques existant.

Public visé: travailleurs dans le domaine des soins de santé, résidents et fellows de neurologie et de physiothérapie, neurologues et physiatres pratiquant dans une université ou dans la communauté, tous s'intéressant à la neurologie neuromusculaire et à la physiothérapie.

13:30	Neuropathies périphériques focales: gros plan sur les difficultés spécifiques de diagnostic et de prise en charge	John Stewart, (Vancouver, BC)
14:00	Discussion	
14:15	Plexopathies brachiale et lombo-sacrée: dilemmes cliniques et variantes atypiques	Kristine Chapman, (Vancouver, BC)
14:45	Discussion	
15:00	Pause	
15:30	Dystrophie myotonique congénitale: analyse et mise à jour par l'étude canadienne de surveillance et de cohorte	Craig Campbell, (London, ON)
16:00	Discussion	
16:15	Neuropathie diabétique: nouvelles directions	Douglas Zochodne, (Calgary, AB)
16:45	Discussion et évaluation	



BIOVISIONARY

As a leading provider of life-saving protein therapeutics, Talecris is dedicated to achieving the next level of excellence. With a strong commitment to innovation, we continue to make advances to enrich patients' lives. Visit us at www.talecris.com.

Talecris
BIOTHERAPEUTICS

INSPIRATION. DEDICATION. INNOVATION.



Mark Hamilton
• *CNSF President*
• *CJNS President*
• *CNSS Past President*



Garth Bray
• *CNSF Vice-President*
• *CJNS Vice-President*
• *CNS*



Brian Wheelock
• *CNSF Vice-President*
• *CJNS Vice-President*
• *CNSS*



Joseph Dooley
• *CNSF Board member*
• *CJNS Board member*
• *CACN President*



Douglas Zochodne
• *CJNS Editor-in-Chief*



Jerome Yager
• *CNSF Board Member*
• *CJNS Board Member*
• *CACN Vice-President*



Derek Fewer
• *CNSF Board Member*
• *CJNS Board Member*
• *CNSS President*



J. Max Findlay
• *CNSF Board Member*
• *CJNS Board Member*
• *CNSS Vice-President*




Andrew Kirk
• *CNSF Board Member*
• *CJNS Board Member*
• *CNS President*



Sam Wiebe
• *Publications Committee
Chair*



Richard Desbiens
• *CNSF Board Member*
• *CJNS Board Member*
• *CNS Vice-President*



George Elleker
• *CNSF Board Member*
• *CJNS Board Member*
• *CSCN President*



Manouchehr Javidan
• *CNSF Board Member*
• *CJNS Board Member*
• *CSCN Vice-President*



Morris Freedman
• *CNSF Board Member*
• *CJNS Board Member*
• *CNSF Past President*



John Stewart
• *CNSF Scientific Program
Committee Chair*



Carmela Tartaglia
• *CNSF Residents' Rep*
• *CJNS Residents' Rep*
• *CNS*



Dan Morin
• *CNSF Board Member*
• *CJNS Board Member*
• *CNSF CEO*



Sue Brien
• *CNSF Professional
Development Committee Chair*
• *CNSS Accreditor*



Charles Tator
• *CBANHC Chair*
• *CNSS*

Legend:

CNSF - Canadian Neurological Sciences Federation; CJNS - Canadian Journal of Neurological Sciences; CNS - Canadian Neurological Society; CNSS - Canadian Neurosurgical Society; CSCN - Canadian Society of Clinical Neurophysiologists; CACN - Canadian Association of Child Neurology; CBANHC - Canadian Brain and Nerve Health Coalition

sanofi-aventis and Bristol-Myers Squibb and are proud to be Gold sponsors of the 2007 Canadian Neurological Sciences Federation Congress.

sanofi aventis



Sanofi-aventis Canada Inc. is an affiliate of the global sanofi-aventis organization, the world's third-largest pharmaceutical company.

In Canada, the company provides medications in the areas of cardiology, thrombosis, oncology, metabolic disorders and internal medicine. It is headquartered in Laval, Quebec, and employs 1,140 people.



Bristol-Myers Squibb

Bristol-Myers Squibb Canada is an indirect wholly owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Company of Canada is a leading provider of medicines to fight cancer; cardiovascular and metabolic disorders; infectious diseases, including HIV/AIDS; nervous system diseases; and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE:BMY). Bristol-Myers Squibb Canada's operations are headquartered in Montreal, Quebec.

The Canadian Neurological Sciences Federation is pleased to recognize our Sponsors* for 2007. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries. Along with support of the Canadian Journal of Neurological Sciences and other initiatives the CNSF maintains throughout the year, these organizations graciously provide unrestricted educational grants to the Annual Congress, this year in Edmonton, Alberta; June 19th – 22, 2007.

La Fédération des sciences neurologiques du Canada est heureuse de reconnaître nos commanditaires pour l'année 2007. Ces organisations forment un partenariat avec la FSNC pour déterminer les causes des maladies et des lésions du système nerveux, pour leur trouver un traitement, et pour s'occuper des patients qui ont ces maladies et lésions. Parallèlement à l'aide financière qu'elles apportent au Journal canadien des sciences neurologiques et à d'autres initiatives que la FSNC aide tout au long de l'année, ces organisations octroient gracieusement des subventions sans condition à but éducatif au congrès annuel qui a lieu cette année à Edmonton, Alberta, du 19 au 22 juin 2007.*

Platinum



Gold



Silver

Hoffman La-Roche

Bronze

Talecris Biotherapeutics
Prestwick Pharmaceuticals
CJNS

Canadian Neurological
Society Foundation
Novartis

Supporters

Bayer Inc.
Merck Frosst
Codman Neuro & Depuy Spine
XLTek
Roxon Medi-Tech
Medtronic of Canada
Genmark Canada

Teva Neuroscience
Valeant Canada Ltd.
Canada Microsurgical
Carl Zeiss Canada
Neurochem
Galen Medical Ltd.

